[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 686
1. Burmeister T, Schwartz S, Bartram CR, Gökbuget N, Hoelzer D, Thiel E, GMALL study group: Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood; 2008 Aug 1;112(3):918-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group.
  • [MeSH-major] Fusion Proteins, bcr-abl / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Humans. Middle Aged. Retrospective Studies

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18650471.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


2. Paulsson K, Cazier JB, Macdougall F, Stevens J, Stasevich I, Vrcelj N, Chaplin T, Lillington DM, Lister TA, Young BD: Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease. Proc Natl Acad Sci U S A; 2008 May 06;105(18):6708-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease.
  • We present here a genome-wide map of abnormalities found in diagnostic samples from 45 adults and adolescents with acute lymphoblastic leukemia (ALL).
  • Importantly, the pattern of deletions resembled that recently reported in pediatric ALL, suggesting that adult, adolescent, and childhood cases may be more similar on the genetic level than previously thought.
  • Our findings provide insights into the leukemogenic process and may be clinically important in adult and adolescent ALL.
  • [MeSH-major] Gene Deletion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. B-Lymphocytes / pathology. Cell Cycle / genetics. Child. Chromosome Aberrations. Genes, Neoplasm. Genome, Human / genetics. Humans. Lymphopoiesis / genetics. Middle Aged. Polymorphism, Single Nucleotide / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):375-8 [15695375.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 15;162(2):176-8 [16213368.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2006 May;20(5):840-6 [16498392.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):748-56 [16470520.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Ann Oncol. 2007 Jan;18 Suppl 1:i3-i8 [17311819.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2327-30 [17095619.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Cancer. 2007 May 15;109(10):2058-67 [17407135.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1258-66 [17443227.001]
  • [Cites] Oncogene. 2007 Jun 21;26(29):4306-18 [17237825.001]
  • [Cites] Hum Mol Genet. 2007 Sep 15;16(18):2215-25 [17613536.001]
  • [Cites] Immunol Cell Biol. 2008 Jan;86(1):47-53 [17998914.001]
  • [Cites] Blood. 2008 Jan 15;111(2):776-84 [17890455.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Sep;47(9):729-39 [18506749.001]
  • [Cites] Leukemia. 2000 Mar;14(3):356-63 [10720126.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1976-82 [11064355.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1337-54 [14508819.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):949-51 [15286789.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2492-8 [15198948.001]
  • [Cites] Ann Med. 2004;36(7):492-503 [15513300.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Jul;16(3):155-63 [8814447.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Nat Genet. 2005 Jun;37 Suppl:S11-7 [15920524.001]
  • (PMID = 18458336.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE9611
  • [Grant] United Kingdom / Cancer Research UK / / A6438; United Kingdom / Cancer Research UK / / A6789
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2373322
  •  go-up   go-down


3. De Braekeleer E, Basinko A, Douet-Guilbert N, Morel F, Le Bris MJ, Berthou C, Morice P, Férec C, De Braekeleer M: Cytogenetics in pre-B and B-cell acute lymphoblastic leukemia: a study of 208 patients diagnosed between 1981 and 2008. Cancer Genet Cytogenet; 2010 Jul 1;200(1):8-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics in pre-B and B-cell acute lymphoblastic leukemia: a study of 208 patients diagnosed between 1981 and 2008.
  • The detection of chromosome abnormalities by conventional cytogenetics, now combined with analyses using fluorescence in situ hybridization (FISH), is an important component in assessing the risk stratification of acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Chromosome Aberrations. Leukemia, B-Cell / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Histone-Lysine N-Methyltransferase. Humans. Middle Aged. Myeloid-Lymphoid Leukemia Protein / genetics. Recurrence. Time Factors. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20513528.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


Advertisement
4. Roecker AM, Allison JC, Kisor DF: Nelarabine: efficacy in the treatment of clinical malignancies. Future Oncol; 2006 Aug;2(4):441-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nelarabine is indicated for the treatment of adult and pediatric patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma whose disease has not responded to, or has relapsed after treatment with, at least two chemotherapy regimens.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Child. Clinical Trials as Topic. Humans

  • COS Scholar Universe. author profiles.
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922610.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine
  • [Number-of-references] 22
  •  go-up   go-down


5. Onishi C, Ohashi K, Sawada T, Nakano M, Kobayashi T, Yamashita T, Akiyama H, Sakamaki H: A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. Int J Hematol; 2010 Apr;91(3):464-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Acute Disease. Adult. Anemia, Aplastic / immunology. Anemia, Aplastic / mortality. Anemia, Aplastic / therapy. Chronic Disease. Female. Humans. Immunocompromised Host. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Male. Middle Aged. Myelodysplastic Syndromes / immunology. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Retrospective Studies. Risk Factors. Stem Cell Transplantation / adverse effects. Stem Cell Transplantation / mortality. Survival Analysis. Transplantation, Homologous. Young Adult

  • Genetic Alliance. consumer health - Chronic Graft versus Host Disease.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2002 Sep;30(5):287-95 [12209350.001]
  • [Cites] Bone Marrow Transplant. 2002 Jun;29(11):903-6 [12080355.001]
  • [Cites] Transplantation. 1985 Aug;40(2):162-6 [3895622.001]
  • [Cites] Haematologica. 2003 Jul;88(7):837-9 [12857569.001]
  • [Cites] Bone Marrow Transplant. 1995 May;15(5):669-77 [7670394.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Apr;11(4):307-13 [15812396.001]
  • [Cites] Transpl Infect Dis. 2009 Aug;11(4):290-7 [19497072.001]
  • [Cites] Transplant Proc. 1998 Dec;30(8):4087-9 [9865306.001]
  • [Cites] Bone Marrow Transplant. 2000 May;25(10 ):1067-71 [10828867.001]
  • [Cites] Int J Hematol. 2003 Jan;77(1):99-102 [12568309.001]
  • [Cites] Bone Marrow Transplant. 1999 Sep;24(5):517-20 [10482936.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2062-8 [10979948.001]
  • [Cites] Transplantation. 1995 Aug 15;60(3):225-32 [7645033.001]
  • [Cites] Int J Hematol. 2008 Jul;88(1):104-10 [18473127.001]
  • [Cites] Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S65-70 [18545247.001]
  • [Cites] Int J Hematol. 2006 Jan;83(1):80-5 [16443558.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):855-64 [9217189.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):465-72 [17618318.001]
  • [Cites] Transplant Proc. 2001 May;33(3):2121-3 [11377471.001]
  • [Cites] Bone Marrow Transplant. 2009 Dec;44(11):739-48 [19377515.001]
  • [Cites] Pharm Res. 1990 Feb;7(2):161-6 [2308896.001]
  • [Cites] Scand J Immunol. 1991 Feb;33(2):161-73 [1826793.001]
  • (PMID = 20217287.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


6. Hunault M, Truchan-Graczyk M, Caillot D, Harousseau JL, Bologna S, Himberlin C, Guyotat D, Berthou C, Casassus P, Baranger L, Béné MC, Ifrah N, Gyan E, GOELAMS Group: Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial. Haematologica; 2007 Dec;92(12):1623-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial.
  • BACKGROUND AND OBJECTIVES: T-lymphoblastic lymphoma is an infrequent disease usually treated as T-acute lymphoblastic leukemia with an induction chemotherapy course and sequential reinduction and maintenance chemotherapy.
  • The T-LBL/ALL-GOELAL02 study evaluated the impact of randomized reinduction chemotherapy against intensified conditioning followed by autologous stem cell transplantation (ASCT), after an induction regimen of the type used for acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Leukocyte Count. Male. Middle Aged. Remission Induction. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18055985.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Italy
  •  go-up   go-down


7. Brentjens RJ: Cellular therapies in acute lymphoblastic leukemia. Curr Opin Mol Ther; 2009 Aug;11(4):375-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular therapies in acute lymphoblastic leukemia.
  • The majority of adult patients with acute lymphoblastic leukemia (ALL) will die from the disease.
  • Although the prognosis for pediatric patients is significantly better than for adult patients with ALL, the prognosis for patients with relapsed or refractory disease is poor in all cases.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Feb 15;105(4):1622-31 [15507526.001]
  • [Cites] Ann Hematol. 2004 Oct;83(10):667-9 [15300405.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Feb;15(2):257-65 [19167686.001]
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(4):393-4 [9051252.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1346-56 [16219571.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4010-7 [19383914.001]
  • [Cites] Curr Opin Immunol. 2009 Apr;21(2):215-23 [19327974.001]
  • [Cites] Br J Haematol. 2008 Dec;143(5):641-53 [18950462.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2276-85 [15564544.001]
  • [Cites] Cytotherapy. 2009;11(3):341-55 [19308771.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1907-14 [17611565.001]
  • [Cites] J Immunother. 2009 Feb-Mar;32(2):169-80 [19238016.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2643-52 [16352804.001]
  • [Cites] Leukemia. 2004 Apr;18(4):676-84 [14961035.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3574-81 [18606875.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Blood Cells Mol Dis. 2004 Jul-Aug;33(1):83-9 [15223016.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):1873-80 [10657636.001]
  • [Cites] J Formos Med Assoc. 1998 Jan;97(1):55-8 [9481066.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):155-63 [16284608.001]
  • [Cites] Blood. 2007 Jun 1;109(11):5058-61 [17317850.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35 [17855649.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10995-1004 [17108138.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1353-66, x [11147227.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):483-93 [18026156.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3110-8 [19059878.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1637-44 [12393484.001]
  • [Cites] Blood. 2004 Feb 1;103(3):767-76 [12958064.001]
  • [Cites] Best Pract Res Clin Haematol. 2008 Sep;21(3):467-83 [18790450.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(4):339-47 [17572712.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1):1-30 [16399566.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2657-63 [16703597.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1631-8 [19104080.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3447-54 [15753458.001]
  • [Cites] Bone Marrow Transplant. 2005 Jul;36(2):163-9 [15937507.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Blood. 2005 Jul 1;106(1):376-83 [15755898.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1819-28 [16932339.001]
  • [Cites] N Engl J Med. 1998 Oct 22;339(17):1186-93 [9780338.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):35-45 [12509765.001]
  • [Cites] Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S18-S24 [18724292.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Dec;14(12):1394-400 [19041062.001]
  • [Cites] Immunogenetics. 2000 Feb;51(2):99-107 [10663572.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1924-32 [17505014.001]
  • [Cites] Nat Med. 2003 Mar;9(3):279-86 [12579196.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Curr Oncol Rep. 2004 Sep;6(5):339-47 [15291974.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1325-31 [16269610.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2265-75 [15564543.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2009-16 [11877273.001]
  • [Cites] Annu Rev Med. 1999;50:369-86 [10073284.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2902-5 [19179301.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3948-55 [7524753.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):473-81 [18176612.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3813-20 [15280199.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(5):511-6 [11019840.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):64-75 [19100369.001]
  • (PMID = 19649982.001).
  • [ISSN] 2040-3445
  • [Journal-full-title] Current opinion in molecular therapeutics
  • [ISO-abbreviation] Curr. Opin. Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA095152; United States / NCI NIH HHS / CA / R01 CA138738; United States / NCI NIH HHS / CA / CA95152; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / CA138738; United States / NCI NIH HHS / CA / P01 CA059350; United States / NCI NIH HHS / CA / CA59350
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 65
  • [Other-IDs] NLM/ NIHMS746468; NLM/ PMC4694559
  •  go-up   go-down


8. Sever M, Jorgensen JL, Gurevich I, Pinheiro M, Verstovsek S: Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient. Leuk Res; 2009 Nov;33(11):e186-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Primary Myelofibrosis / diagnosis. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19482354.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS679751; NLM/ PMC4406375
  •  go-up   go-down


9. Jinnai I, Sakura T, Tsuzuki M, Maeda Y, Usui N, Kato M, Okumura H, Kyo T, Ueda Y, Kishimoto Y, Yagasaki F, Tsuboi K, Horiike S, Takeuchi J, Iwanaga M, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Ohno R: Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study. Int J Hematol; 2010 Oct;92(3):490-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study.
  • We designed a treatment protocol for newly diagnosed adult acute lymphoblastic leukemia (ALL) in the pre-imatinib era, employing intensified consolidation therapy with a total of 330 mg/m² doxorubicin and adopting slightly modified induction and maintenance regimen of the CALGB 8811 study.
  • The present treatment regimen could not show a better outcome than that of our previous JALSG-ALL93 study for adult ALL.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Female. Hematopoietic Stem Cell Transplantation. Humans. Japan. Male. Middle Aged. Philadelphia Chromosome. Prognosis. Remission Induction. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2563-72 [18156492.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Br J Haematol. 2009 Jun;146(1):76-85 [19438471.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1556-64 [9716583.001]
  • [Cites] Control Clin Trials. 1996 Aug;17(4):343-6 [8889347.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):911-8 [19124805.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5136-42 [17344466.001]
  • [Cites] Int J Hematol. 2009 Jan;89(1):3-13 [19093166.001]
  • [Cites] Haematologica. 1996 Mar-Apr;81(2):127-31 [8641640.001]
  • [Cites] Semin Hematol. 1994 Jan;31(1):1-15 [8122133.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1375-82 [18988865.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1646-54 [18502832.001]
  • [Cites] Eur J Cancer. 1996 Aug;32A(9):1544-50 [8911116.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Leuk Res. 2007 Jul;31(7):907-14 [17005250.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1350-7 [17640299.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • (PMID = 20830614.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


10. Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K, Allen CG, Gale RE, Buck G, Richards S, Paietta E, Rowe JM, Tallman MS, Goldstone AH, Ferrando AA, Linch DC: Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol; 2009 Sep 10;27(26):4352-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
  • PURPOSE: Notch pathway activation by mutations in either NOTCH1 and/or FBXW7 is one of the most common molecular events in T-cell acute lymphoblastic leukemia (T-ALL) and, in pediatric disease, predicts for favorable outcome.
  • Their prognostic significance in adult T-ALL is unclear.
  • We sought to evaluate the outcome according to mutation status of patients with adult T-ALL treated on the United Kingdom Acute Lymphoblastic Leukaemia XII (UKALLXII)/Eastern Cooperative Oncology Group (ECOG) E2993 protocol.
  • METHODS: NOTCH1 and FBXW7 were screened by a combination of denaturing high-performance liquid chromatography and sequencing in 88 adult patients with T-ALL treated on the UKALLXII/ECOG E2993 protocol and compared with clinical characteristics and outcome.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Adolescent. Adult. Chromatography, High Pressure Liquid / methods. DNA Mutational Analysis. Disease-Free Survival. Female. Follow-Up Studies. Gene Frequency. Genotype. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Treatment Outcome. United Kingdom. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1262-70 [17456725.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6964-9 [18056171.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Leuk Res. 2008 Nov;32(11):1751-5 [18485478.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4386-93 [12036866.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1126-34 [12414341.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2149-56 [14576730.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] Leukemia. 1998 Apr;12(4):463-73 [9557602.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • (PMID = 19635999.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00002514
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856; United States / NCI NIH HHS / CA / R01 CA129382; United Kingdom / Medical Research Council / / ; United Kingdom / Medical Research Council / / G0500389; United States / NCI NIH HHS / CA / R01CA120196; United States / NCI NIH HHS / CA / R01CA129382; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / R01 CA120196-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; EC 2.3.2.27 / Ubiquitin-Protein Ligases; EC 6.3.2.19 / FBXW7 protein, human
  • [Other-IDs] NLM/ PMC2744275
  •  go-up   go-down


11. Jabbour EJ, Faderl S, Kantarjian HM: Adult acute lymphoblastic leukemia. Mayo Clin Proc; 2005 Nov;80(11):1517-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia.
  • Much progress has been made in understanding the biology of and therapy for acute lymphoblastic leukemia (ALL).
  • Development of new drugs and agents tailored to subset-specific cytogenetic-molecular characteristics is vital to the therapeutic success in adult ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Humans. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16295033.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


12. Matsushita M, Takeuchi S, Yang Y, Yoshino N, Tsukasaki K, Taguchi H, Koeffler HP, Seo H: Methylation of the MLH1 gene in hematological malignancies. Oncol Rep; 2005 Jul;14(1):191-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genomic DNA was extracted from 31 patients with adult T-cell leukemia/lymphoma (ATL), 9 patients with acute lymphoblastic leukemia (ALL) who had MSI, and 12 leukemia and lymphoma cell lines with MSI.
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Antimetabolites, Antineoplastic / pharmacology. Azacitidine / pharmacology. Carrier Proteins. Cell Line, Tumor. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. DNA-Binding Proteins / genetics. Gene Expression Regulation, Neoplastic / drug effects. Humans. Jurkat Cells. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / pathology. MutS Homolog 2 Protein. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Promoter Regions, Genetic / genetics. Proto-Oncogene Proteins / genetics. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944788.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antimetabolites, Antineoplastic; 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Neoplasm; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; M801H13NRU / Azacitidine
  •  go-up   go-down


13. Trikalinos NA, Soupir CP, Dey BR: Lineage switch of acute lymphocyctic leukaemia with t(4;11)(q21;q23) into acute myeloid leukaemia in an adult patient after allogeneic stem cell transplantation. Br J Haematol; 2009 Apr;145(2):262-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lineage switch of acute lymphocyctic leukaemia with t(4;11)(q21;q23) into acute myeloid leukaemia in an adult patient after allogeneic stem cell transplantation.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 4. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Disease Progression. Female. Humans

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208102.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


14. Tamai H, Yamaguchi H, Hamaguchi H, Yagasaki F, Bessho M, Kobayashi T, Akiyama H, Sakamaki H, Takahashi S, Tojo A, Ohmine K, Ozawa K, Okumura H, Nakao S, Arai A, Miura O, Toyota S, Gomi S, Murai Y, Usui N, Miyazawa K, Ohyashiki K, Takahashi N, Sawada K, Kato A, Oshimi K, Inokuchi K, Dan K: Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study. Int J Hematol; 2008 Mar;87(2):195-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study.
  • To clarify the clinical features of adult patients with acute leukemia (AL) with 11q23 abnormalities, we performed a retrospective analysis of data from 58 adult Japanese patients: 51 with acute myeloid leukemia (AML), and 7 with acute lymphoblastic leukemia (ALL).
  • However, further studies involving a large number of cases are required to assess the effect of allo-HSCT on adult AL with 11q23 abnormalities.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Cohort Studies. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4532-8 [9373264.001]
  • [Cites] Leukemia. 1994 Nov;8(11):1918-22 [7967737.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6236-9 [8016145.001]
  • [Cites] Leukemia. 1998 May;12(5):801-4 [9593284.001]
  • [Cites] Leukemia. 1995 Aug;9(8):1299-304 [7643616.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1013-7 [10400416.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10735-9 [1720549.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):298-306 [15323147.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):55-9 [9426057.001]
  • [Cites] Leuk Res. 1999 Jun;23(6):585-8 [10374852.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3254-61 [12149299.001]
  • [Cites] Leuk Res. 2000 Jun;24(6):481-6 [10781681.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12110-4 [7991593.001]
  • [Cites] Leukemia. 1998 May;12(5):805-10 [9593285.001]
  • [Cites] Hum Pathol. 1987 Mar;18(3):211-25 [3546071.001]
  • [Cites] Blood. 1994 Sep 15;84(6):1747-52 [8080983.001]
  • [Cites] Leukemia. 1995 May;9(5):762-9 [7769837.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] N Engl J Med. 1993 Sep 23;329(13):909-14 [8361504.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2395-402 [12805060.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2327-30 [8162575.001]
  • [Cites] Leukemia. 1998 May;12(5):788-91 [9593282.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:118-45 [15561680.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3705-11 [8260707.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5695-707 [11607819.001]
  • [Cites] Haematologica. 1998 Apr;83(4):350-7 [9592986.001]
  • [Cites] Br J Haematol. 2001 Sep;114(3):539-43 [11552977.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5624-8 [8242616.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1420-7 [15368330.001]
  • [Cites] Oncogene. 1993 Nov;8(11):3085-92 [8414510.001]
  • [Cites] Leukemia. 1998 May;12(5):792-800 [9593283.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Leukemia. 1998 Jan;12(1):25-33 [9436917.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2073-6 [7662954.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):614-26 [10468849.001]
  • [Cites] J Clin Invest. 1994 Jan;93(1):429-37 [8282816.001]
  • (PMID = 18253706.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


15. Steiner M, Attarbaschi A, König M, Gadner H, Haas OA, Mann G: Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome. Pediatr Hematol Oncol; 2005 Jan-Feb;22(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Equal frequency of TEL/AML1+ acute lymphoblastic leukemia in children with and without Down syndrome.
  • Constitutional trisomy 21 is the most prominent predisposing factor to childhood leukemia, whereas the t(12;21)(p13;q22) with its molecular genetic counterpart, the TEL/AML1 fusion gene, is the most common acquired chromosomal rearrangement in childhood B-cell precursor (BCP) acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Down Syndrome / genetics. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Austria / epidemiology. Child, Preschool. Chromosomes, Human, Pair 21 / genetics. Core Binding Factor Alpha 2 Subunit. Female. Humans. In Situ Hybridization, Fluorescence. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedIn] Pediatr Hematol Oncol. 2005 Apr-May;22(3):229-34 [16020107.001]
  • (PMID = 15770827.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


16. Navid F, Billups C, Liu T, Krasin MJ, Rodriguez-Galindo C: Second cancers in patients with the Ewing sarcoma family of tumours. Eur J Cancer; 2008 May;44(7):983-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second cancers in patients with the Ewing sarcoma family of tumours.
  • BACKGROUND: Patients are at risk of second malignancies (SM) after treatment for Ewing sarcoma family of tumours (ESFT).
  • METHODS: We performed a retrospective review of 237 patients with ESFT treated at our institution from September 1979 through to February 2004.
  • Cumulative incidence (CI) of SM by the type of malignancy and treatment was estimated.
  • RESULTS: Twelve patients with SM were identified.
  • Secondary leukaemia (SL) developed in 8 patients (2 ALL, 6 MDS/AML), a median 2.6 years (range 1.4-19.6 years) after diagnosis of ESFT.
  • Four patients had secondary solid tumours, a median 8.0 years (range 7.4-9.4 years) after the ESFT diagnosis.
  • Five- and 10-year estimates of the CI of SM were 3.0+/-1.1% and 4.7+/-1.5%, respectively.
  • Patients treated on recent protocols with higher cumulative doses or an increased dose intensity of alkylators and epipodophyllotoxins and the use of G-CSF had a higher estimated CI of SL than those in earlier studies (5-year CI 6.4+/-2.4% versus 0.0+/-0.0%, respectively, P=0.004).
  • CONCLUSIONS: Patients with ESFT are at risk for SM after treatment.
  • The cumulative incidence of SM is higher with the current treatment protocols and may be related to the intensification of chemotherapeutic agents.

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2000 Jul-Aug;22(4):321-9 [10959902.001]
  • [Cites] N Engl J Med. 1987 Sep 3;317(10):588-93 [3475572.001]
  • [Cites] Clin Radiol. 2001 Jan;56(1):22-9 [11162693.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2134-41 [11304765.001]
  • [Cites] Med Pediatr Oncol. 2001 May;36(5):525-35 [11340607.001]
  • [Cites] Leuk Lymphoma. 2000 Nov;39(5-6):465-75 [11342330.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1619-30 [11822764.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Apr;33(4):331-45 [11921269.001]
  • [Cites] Blood. 2002 Jul 15;100(2):427-34 [12091332.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2243-51 [12441260.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1195-204 [12663705.001]
  • [Cites] Am J Hematol. 2003 May;73(1):33-6 [12701117.001]
  • [Cites] Blood. 2003 May 15;101(10):3862-7 [12531808.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(1):31-4 [12815475.001]
  • [Cites] Exp Hematol. 2004 Jan;32(1):122-30 [14725909.001]
  • [Cites] Int J Cancer. 2004 May 20;110(1):87-93 [15054872.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] J Natl Cancer Inst. 1979 Jun;62(6):1401-6 [220452.001]
  • [Cites] Blood. 1981 Oct;58(4):759-67 [7272506.001]
  • [Cites] J Clin Oncol. 1983 Jan;1(1):45-51 [6668483.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):325-45 [3950675.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1748-57 [3783201.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):180-90 [10458232.001]
  • [Cites] J Clin Oncol. 1987 Nov;5(11):1822-6 [3316515.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):136-42 [2787477.001]
  • [Cites] Br J Haematol. 1990 Jul;75(3):442-4 [2248673.001]
  • [Cites] Blood. 1991 Aug 15;78(4):1147-8 [1651134.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):156-63 [1309379.001]
  • [Cites] Clin Orthop Relat Res. 1992 Jan;(274):275-81 [1729013.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1737-42 [1403056.001]
  • [Cites] Med Pediatr Oncol. 1994;22(4):296-7 [8107665.001]
  • [Cites] Med Pediatr Oncol. 1994;23(5):406-12 [8084307.001]
  • [Cites] Leukemia. 1996 Mar;10(3):460-5 [8642862.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2818-25 [8874344.001]
  • [Cites] Med Pediatr Oncol. 1998 Apr;30(4):259-60 [9473762.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3016-20 [9738570.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):379-84 [9788419.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23(1):21-5 [10037046.001]
  • [Cites] Bone Marrow Transplant. 1999 Oct;24(7):735-9 [10516676.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Feb;42(2):107-16 [15543619.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Oct;27(10):517-20 [16217253.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):183-9 [16299545.001]
  • [Cites] Leukemia. 2006 Feb;20(2):239-46 [16341039.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1846-56 [16541446.001]
  • [Cites] N Engl J Med. 2006 May 11;354(19):2034-45 [16687716.001]
  • [Cites] Pediatr Blood Cancer. 2006 Dec;47(7):931-5 [16155933.001]
  • [Cites] Blood. 2007 Jan 1;109(1):46-51 [16985182.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 7;99(3):196-205 [17284714.001]
  • [Cites] Leuk Lymphoma. 2000 Mar;37(1-2):213-8 [10721789.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Nov-Dec;21(6):486-93 [10598659.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3108-14 [10963639.001]
  • (PMID = 18353632.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA23099; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P30 CA021765-29; United States / NCI NIH HHS / CA / P30 CA021765
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS51653; NLM/ PMC2423466
  •  go-up   go-down


17. Mishra P, Kumar R, Mahapatra M, Sharma S, Dixit A, Chaterjee T, Choudhry DR, Saxena R, Choudhry VP: Tuberculosis in acute leukemia: a clinico-hematological profile. Hematology; 2006 Oct;11(5):335-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with AML were more likely to develop TB as compared to patients with acute lymphoblastic leukemia (ALL) despite the wider use of steroids and radiotherapy in ALL protocols {OR 4.41 (CI 0.53-36.44)}.
  • [MeSH-minor] Acute Disease. Adult. Antitubercular Agents / therapeutic use. Female. Humans. Incidence. Leukemia, Myeloid. Male. Neutropenia. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607583.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


18. Trojan J, Mousset S, Caspary WF, Hoepffner N: An infected esophageal duplication cyst in a patient with non-Hodgkin's lymphoma mimicking persistent disease. Dis Esophagus; 2005;18(4):287-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An infected esophageal duplication cyst in a patient with non-Hodgkin's lymphoma mimicking persistent disease.
  • We report a patient with non-Hodgkin's lymphoma, who was considered to have persistent disease in the posterior mediastinum based on CT scans.

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16128789.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Vakiani E, Savage DG, Pile-Spellman E, El-Tamer M, Singh IR, Murty VS, Alobeid B, Bhagat G: T-Cell lymphoblastic lymphoma presenting as bilateral multinodular breast masses: a case report and review of the literature. Am J Hematol; 2005 Nov;80(3):216-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-Cell lymphoblastic lymphoma presenting as bilateral multinodular breast masses: a case report and review of the literature.
  • Non-Hodgkin lymphoma of T-cell lineage involving the breast is rare.
  • We report on a 41-year-old woman with T-cell lymphoblastic lymphoma who presented with multiple bilateral breast masses.
  • [MeSH-major] Breast Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Cranial Irradiation. Diagnosis, Differential. Female. Humans. Radiotherapy, Adjuvant. Remission Induction / methods

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247747.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA149719
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. González Pérez P, Serrano-Pozo A, Franco-Macías E, Montes-Latorre E, Gómez-Aranda F, Campos T: Vincristine-induced acute neurotoxicity versus Guillain-Barré syndrome: a diagnostic dilemma. Eur J Neurol; 2007 Jul;14(7):826-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a patient with acute lymphoblastic leukaemia who, after the initiation of treatment with vincristine (VCR), developed a fulminant motor polyradiculoneuropathy resembling an axonal variant of Guillain-Barré syndrome (GBS).
  • [MeSH-minor] Action Potentials. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Diagnosis, Differential. Erectile Dysfunction / chemically induced. Fatal Outcome. Humans. Hydrocortisone / administration & dosage. Male. Methotrexate / administration & dosage. Paraparesis / chemically induced. Paresthesia / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisone / administration & dosage. Remission Induction. Urination Disorders / chemically induced

  • Genetic Alliance. consumer health - Guillain-Barre Syndrome.
  • MedlinePlus Health Information. consumer health - Guillain-Barre Syndrome.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594344.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


21. Kosmidis S, Baka M, Bouhoutsou D, Doganis D, Kallergi C, Douladiris N, Pourtsidis A, Varvoutsi M, Saxoni-Papageorgiou F, Vasilatou-Kosmidis H: Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL. Pediatr Blood Cancer; 2008 Mar;50(3):528-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Agammaglobulinemia / chemically induced. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia-Lymphoma, Adult T-Cell / immunology. Neutropenia / chemically induced. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17853465.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antigens, CD
  •  go-up   go-down


22. Wrzesień-Kuś A, Robak T, Pluta A, Zwolińska M, Wawrzyniak E, Wierzbowska A, Skotnicki A, Jakubas B, Hołowiecki J, Nowak K, Kuliczkowski K, Mazur G, Haus O, Dmoszyńska A, Adamczyk-Cioch M, Jedrzejczak WW, Paluszewska M, Konopka L, Pałynyczko G: Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG). Ann Hematol; 2006 Jun;85(6):366-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
  • Patients with Philadelphia chromosome-positive (Ph+) and/or BCR-ABL+ acute lymphoblastic leukemia (ALL) have extremely poor prognoses.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation. Humans. Karyotyping. Male. Methotrexate / administration & dosage. Middle Aged. Poland. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523310.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; E7WED276I5 / 6-Mercaptopurine; EC 2.7.10.2 / Fusion Proteins, bcr-abl; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


23. Ma R, Xu YG, Yang XH, Hu XM, Li L, Tang XD, Zhang SS, Xu S, Wang HZ, Liu F: [Immunophenotypic features in leukemia of NK cell series]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb;14(1):35-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient has been diagnosed as myeloid/NK cell precursor acute leukemia, two patients were blastic NK cell leukemia, one was supposed to be NK-like T-cell lymphoma/leukemia, while another one was large granular lymphocyte leukemia (LGLL).

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584587.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


24. Nakamura S, Okinaka K, Hirano I, Ono T, Sugimoto Y, Shigeno K, Fujisawa S, Shinjo K, Ohnishi K: KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells. Leuk Res; 2008 Sep;32(9):1358-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
  • [MeSH-major] Cell Cycle / physiology. Cell Proliferation. Intracellular Signaling Peptides and Proteins / metabolism. Intracellular Signaling Peptides and Proteins / physiology. Leukemia, Myeloid, Acute / metabolism. Myelodysplastic Syndromes / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Protein-Serine-Threonine Kinases / physiology
  • [MeSH-minor] Adult. Aged. Blotting, Western. Bone Marrow / metabolism. Bone Marrow / pathology. Cells, Cultured. Cyclin-Dependent Kinase Inhibitor p27. Humans. Immunoprecipitation. Leukocytes, Mononuclear / metabolism. Leukocytes, Mononuclear / pathology. Middle Aged. Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384876.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / UHMK1 protein, human
  •  go-up   go-down


25. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I, Barredo JC: Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer; 2007 Jul 10;6:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
  • BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy affecting children.
  • The aim of this study was to investigate the AMP activated protein kinase (AMPK) as a potential target in childhood acute lymphoblastic leukemia (ALL) subtypes characterized by non-random translocation signature profiles.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2005 Dec 9;310(5754):1642-6 [16308421.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):298-306 [15549091.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Dev Cell. 2006 May;10(5):549-61 [16678772.001]
  • [Cites] BMC Cancer. 2006;6:132 [16707018.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:133-41 [17124052.001]
  • [Cites] Circ Res. 2000 May 26;86(10):1069-77 [10827137.001]
  • [Cites] Hum Mol Genet. 2000 Jul 22;9(12):1721-7 [10915759.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):95-105 [10998351.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 21;287(2):562-7 [11554766.001]
  • [Cites] BMJ. 2002 Feb 2;324(7332):283-7 [11823363.001]
  • [Cites] Science. 2002 Feb 15;295(5558):1291-4 [11847341.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):23977-80 [11997383.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] Oncology. 2004;67(5-6):476-9 [15714005.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2441-8 [15781660.001]
  • [Cites] Mol Cell. 2005 Apr 29;18(3):283-93 [15866171.001]
  • [Cites] Hum Mol Genet. 2005 May 15;14(10):1283-92 [15800014.001]
  • [Cites] Circ Res. 2005 Oct 14;97(8):837-44 [16151020.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7475-81 [16288294.001]
  • [Cites] J Biol Chem. 2005 Nov 25;280(47):39582-93 [16176927.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25226-32 [11994296.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):6082-90 [12203120.001]
  • [Cites] FEBS Lett. 2002 Aug 28;526(1-3):38-42 [12208500.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1435-8 [12364621.001]
  • [Cites] Biochem Soc Trans. 2003 Feb;31(Pt 1):162-8 [12546677.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1382-8 [12649203.001]
  • [Cites] Leukemia. 2003 Apr;17(4):700-6 [12682627.001]
  • [Cites] J Mol Endocrinol. 2003 Apr;30(2):151-61 [12683939.001]
  • [Cites] FEBS Lett. 2003 Jul 3;546(1):113-20 [12829246.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28434-42 [12764152.001]
  • [Cites] Genes Dev. 2003 Aug 15;17(16):1969-78 [12893778.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):257-62 [14585353.001]
  • [Cites] Curr Biol. 2003 Nov 11;13(22):2004-8 [14614828.001]
  • [Cites] Cell. 2003 Nov 26;115(5):577-90 [14651849.001]
  • [Cites] Trends Biochem Sci. 2004 Jan;29(1):32-8 [14729330.001]
  • [Cites] J Biol. 2003;2(4):28 [14511394.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):91-9 [15261145.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 13;321(1):161-7 [15358229.001]
  • [Cites] Eur J Biochem. 1989 Dec 8;186(1-2):123-8 [2574667.001]
  • [Cites] FEBS Lett. 1994 Oct 10;353(1):33-6 [7926017.001]
  • [Cites] Eur J Biochem. 1995 Apr 15;229(2):558-65 [7744080.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Jun;277(3):1397-401 [8667202.001]
  • [Cites] Eur J Biochem. 1997 Jun 1;246(2):259-73 [9208914.001]
  • [Cites] FEBS Lett. 1997 Jun 16;409(3):452-6 [9224708.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):392-8 [9408756.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):38-43 [9425897.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):184-7 [9428765.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Feb 24;243(3):821-6 [9500985.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15653-8 [9861025.001]
  • [Cites] Curr Opin Pediatr. 1999 Feb;11(1):33-8 [10084082.001]
  • [Cites] Trends Biochem Sci. 1999 Jan;24(1):22-5 [10087918.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48707-15 [15355997.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 3;340(1):43-7 [16377306.001]
  • (PMID = 17623090.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098152; United States / NCI NIH HHS / CA / CA098152-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole; 0 / Antineoplastic Agents; 0 / Imidazoles; 0 / Multienzyme Complexes; 0 / Neoplasm Proteins; 0 / Prodrugs; 0 / Pyridines; 0 / Ribonucleotides; 24386-93-4 / 5-iodotubercidin; 360-97-4 / Aminoimidazole Carboxamide; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / AMP-Activated Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; F0X88YW0YK / AICA ribonucleotide; M351LCX45Y / Tubercidin; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1948012
  •  go-up   go-down


26. Gandemer V, Auclerc MF, Perel Y, Vannier JP, Le Gall E, Demeocq F, Schmitt C, Piguet C, Stephan JL, Lejars O, Debre M, Jonveaux P, Cayuela JM, Chevret S, Leverger G, Baruchel A, FRALLE group: Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study. BMC Cancer; 2009;9:14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.
  • BACKGROUND: We explored the heterogeneity of philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL) in a study of the effect of early features on prognosis in children.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Bone Marrow / drug effects. Leukocyte Count. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage
  • [MeSH-minor] Acute Disease. Adolescent. Age Factors. Anthracyclines. Asparaginase. Benzamides. Bone Marrow Transplantation. Child. Child, Preschool. Cortisone. Female. Humans. Imatinib Mesylate. Infant. Male. Prednisone / administration & dosage. Recurrence. Treatment Outcome. Vincristine. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Apr;19(4):628-35 [15744351.001]
  • [Cites] Br J Haematol. 2005 Apr;129(1):35-44 [15801953.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1341-9 [17312329.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2791-3 [17119111.001]
  • [Cites] Haematologica. 2007 Dec;92(12):1723-4 [18056006.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):447-53 [17968326.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1496-503 [18349402.001]
  • [Cites] Blood. 2002 Jul 1;100(1):43-7 [12070006.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1700-6 [12970767.001]
  • [Cites] Bone Marrow Transplant. 2004 Jan;33(1):39-45 [14566329.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1043-9 [14525776.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1292-5 [7632935.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1493-6 [9305603.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7209-19 [16243790.001]
  • (PMID = 19144139.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 5J49Q6B70F / Vincristine; 8A1O1M485B / Imatinib Mesylate; EC 3.5.1.1 / Asparaginase; V27W9254FZ / Cortisone; VB0R961HZT / Prednisone; FRALLE 93 protocol
  • [Other-IDs] NLM/ PMC2629767
  • [Investigator] Pautard B; Bauduer JF; Abgrall JF; Berthou C; Paillard C; Kanold J; Couillault G; Damay M; de Lumley L; Michel G; Thuret I; Chambost H; Bordigoni P; Sommel D; Leblanc T; Schaison G; Tabone MD; Donadieu J; Landman-Parker J; Auvrignon A; Thomas C; Fisher A; Dommergues JP; Bader-Meunier B; Bernaudin F; Lemerle S; Choulot J; Doireau V; Edan C; Bergeron C; Schneider P; Lamagnere JP; Berger C; Cornu G; Vermylen C
  •  go-up   go-down


27. Xu W, Li JY, Wu YJ, Sheng RL, Lu FX: [Expression of Ki-67 and Bcl-2 in adults and children with acute lymphoblastic leukemia and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct;14(5):887-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of Ki-67 and Bcl-2 in adults and children with acute lymphoblastic leukemia and its clinical significance].
  • To evaluate the expressions of proliferative antigen Ki-67 and apoptosis-antagonizing protein Bcl-2 as well as their clinical significance, immunohistochemistry staining with SAP was used to detect Ki-67 antigen and Bcl-2 protein in 18 cases of children with acute lymphoblastic leukemia (ALL) and 43 cases of adults with ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096882.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


28. De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, Vandenberghe P, Odero MD, Marynen P, Cools J: In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia. Haematologica; 2008 Apr;93(4):533-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
  • BACKGROUND: Activating NOTCH1 mutations are common in T-cell acute lymphoblastic leukemia.
  • We further documented the effects of gamma-secretase inhibitor treatment on T-cell acute lymphoblastic leukemia cell lines and tested whether combining gamma-secretase inhibitors with other anti-cancer drugs offers a therapeutic advantage.
  • DESIGN AND METHODS: The effect of gamma-secretase inhibitor treatment and combinations of gamma-secretase inhibitors with chemotherapy or glucocorticoids was assessed on T-cell acute lymphoblastic leukemia cell lines.
  • We sequenced NOTCH1 in T-cell acute lymphoblastic leukemia cases with ABL1 fusions and tested combinations of gamma-secretase inhibitors and the ABL1 inhibitor imatinib in a T-cell acute lymphoblastic leukemia cell line.
  • RESULTS: gamma-secretase inhibitor treatment for 5-7 days reversibly inhibited cell proliferation, caused cell cycle block in sensitive T-cell acute lymphoblastic leukemia cell lines, and caused differentiation of some T-cell acute lymphoblastic leukemia cell lines.
  • The cytotoxic effects of the chemotherapeutic agent vincristine were not significantly enhanced by addition of gamma-secretase inhibitors to T-cell acute lymphoblastic leukemia cell lines, but gamma-secretase inhibitor treatment sensitized cells to the effect of dexamethasone.
  • NOTCH1 mutations were identified in all T-cell acute lymphoblastic leukemia patients with ABL1 fusions and in a T-cell acute lymphoblastic leukemia cell line expressing NUP214-ABL1.
  • CONCLUSIONS: Short-term treatment of T-cell acute lymphoblastic leukemia cell lines with gamma-secretase inhibitors had limited effects on cell proliferation and survival.
  • Combinations of gamma-secretase inhibitors with other drugs may be required to obtain efficient therapeutic effects in T-cell acute lymphoblastic leukemia, and not all combinations may be useful.
  • [MeSH-major] Amyloid Precursor Protein Secretases / antagonists & inhibitors. Antineoplastic Agents / pharmacology. Benzodiazepinones / pharmacology. Carbamates / pharmacology. Dipeptides / pharmacology. Enzyme Inhibitors / pharmacology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Receptor, Notch1 / antagonists & inhibitors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Apr;93(4):493-7 [18379008.001]
  • (PMID = 18322257.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / 2-(((3,5-difluorophenyl)acetyl)amino)-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)propanamide; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Benzodiazepinones; 0 / Carbamates; 0 / DNA, Neoplasm; 0 / Dipeptides; 0 / Enzyme Inhibitors; 0 / L 685458; 0 / NOTCH1 protein, human; 0 / NUP214-ABL1 fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / Receptor, Notch1; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8A1O1M485B / Imatinib Mesylate; EC 3.4.- / Amyloid Precursor Protein Secretases; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


29. Aljurf M, Zaidi SZ: Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies. Biol Blood Marrow Transplant; 2005 Oct;11(10):739-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies.
  • Adult T-cell lymphoblastic lymphoma is a relatively rare aggressive type of non-Hodgkin lymphoma with frequent involvement of extranodal sites.
  • The collective experience in the management of adult T-cell lymphoblastic lymphoma suggests a good outcome for patients with no adverse prognostic factors who are treated with an acute lymphocytic leukemia-like treatment strategy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Central Nervous System Neoplasms / therapy. Graft vs Tumor Effect. Humans. Mediastinal Neoplasms / therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16182175.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 114
  •  go-up   go-down


30. Chen LJ, Li JY, Wu YJ, Yang H, Qian SX, Wu HX, Lu H, Xu W, Sheng RL: [Immunophenotyping characteristics of T-cell acute lymphoblastic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug;15(4):692-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunophenotyping characteristics of T-cell acute lymphoblastic leukemia].
  • The objective of this study was to investigate the immunophenotypic characteristics of T-cell acute lymphoblastic leukemia (T-ALL).
  • The expression of CD3 in child T-ALL was higher than that in adult T-ALL, whereas the expression of CD33 in children was lower than that in adults.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708784.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3
  •  go-up   go-down


31. Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, Lange T, Hochhaus A, Wystub S, Brück P, Hoelzer D, Ottmann OG: Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood; 2007 Jul 15;110(2):727-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
  • Acquired imatinib resistance in advanced Philadelphia-positive acute lymphoblastic leukemia (Ph(+) ALL) has been associated with mutations in the kinase domain (KD) of BCR-ABL.
  • Patients enrolled in the German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL) trial ADE10 for newly diagnosed elderly Ph(+) ALL were retrospectively examined for the presence of BCR-ABL KD mutations by denaturing high-performance liquid chromatography (D-HPLC), cDNA sequencing, and allele-specific polymerase chain reaction (PCR).
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Mutation. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405907.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


32. Chiaretti S, Tavolaro S, Ghia EM, Ariola C, Matteucci C, Elia L, Maggio R, Messina M, Ricciardi MR, Vitale A, Ritz J, Mecucci C, Guarini A, Foà R: Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis. Haematologica; 2007 May;92(5):619-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis.
  • BACKGROUND AND OBJECTIVES: Recent data have highlighted an involvement of ABL1 in T-cell acute lymphoblastic leukemia (T-ALL).
  • NUP214-ABL1, in adult T-ALL.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Leukemic. Genes, abl. Leukemia-Lymphoma, Adult T-Cell / genetics. Neoplasm Proteins / biosynthesis. Oncogene Proteins, Fusion / biosynthesis. Proto-Oncogene Proteins c-abl / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Chromosomal Proteins, Non-Histone / biosynthesis. Chromosomal Proteins, Non-Histone / genetics. Clinical Trials as Topic / statistics & numerical data. Female. Fusion Proteins, bcr-abl / biosynthesis. Fusion Proteins, bcr-abl / genetics. Homeodomain Proteins / biosynthesis. Homeodomain Proteins / genetics. Humans. In Situ Hybridization, Fluorescence. Intracellular Signaling Peptides and Proteins / genetics. Male. Multicenter Studies as Topic / statistics & numerical data. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. Oncogene Proteins / biosynthesis. Oncogene Proteins / genetics. Polymerase Chain Reaction. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Proto-Oncogene Proteins / biosynthesis. Proto-Oncogene Proteins / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488685.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / Dek protein, human; 0 / EML1-ABL1 fusion protein, human; 0 / Homeodomain Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / NUP214-ABL1 fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / STIL protein, human; 0 / TLX3 protein, human; 143275-75-6 / TLX1 protein, human; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.10.2 / Proto-Oncogene Proteins c-abl
  •  go-up   go-down


33. Zheng YY, Chen G, Zhou XG, Jin Y, Xie JL, Zhang SH, Zhang YN: [Retrospective analysis of 4 cases of the so-called blastic NK-cell lymphoma, with reference to the 2008 WHO classification of tumours of haematopoietic and lymphoid tissues]. Zhonghua Bing Li Xue Za Zhi; 2010 Sep;39(9):600-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retrospective analysis of 4 cases of the so-called blastic NK-cell lymphoma, with reference to the 2008 WHO classification of tumours of haematopoietic and lymphoid tissues].
  • OBJECTIVE: To study the clinical and pathologic features of 4 cases of the so-called blastic natural killer (NK)-cell lymphoma, with reference to the 2008 WHO classification of tumours of haematopoietic and lymphoid tissues.
  • METHODS: The clinical, pathologic and immunohistochemical findings (EliVision method) of 4 cases of blastic NK-cell lymphoma (previously diagnosed according to the 2001 WHO classification) were retrospectively analyzed and reclassified with a special reference to the 2008 WHO classification.
  • RESULTS: The 4 cases of hematologic malignancy studied were characterized by the presence of medium-sized blastic lymphoma cells, CD56 expression, and absence of lineage-specific B-cell, T-cell and myeloid cell markers.
  • According to the 2001 WHO classification, they fell into the category of blastic NK-cell lymphoma.
  • This case was provisionally classified as a ambiguous lineage leukemia-NK cell lymphoblastic leukemia/lymphoma.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Skin Neoplasms / classification. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Antigens, CD56 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Humans. Interleukin-3 Receptor alpha Subunit / metabolism. Killer Cells, Natural / pathology. Middle Aged. Retrospective Studies. World Health Organization. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092587.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Interleukin-3 Receptor alpha Subunit
  •  go-up   go-down


34. Pugliese L, Bernardini I, Pacifico N, Peverini M, Damaskopoulou E, Cataldi S, Albi E: Severe hypocholesterolaemia is often neglected in haematological malignancies. Eur J Cancer; 2010 Jun;46(9):1735-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In fact we have demonstrated that low cholesterol level in the culture medium was related to the neoplastic cellular growth, suggesting a greater use by lymphoma cells for their proliferation.
  • [MeSH-major] Cholesterol / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • [MeSH-minor] Adult. Anticholesteremic Agents / pharmacology. Cell Line. Cell Proliferation / drug effects. Cell Survival / drug effects. Female. Humans. Lovastatin / analogs & derivatives. Lovastatin / pharmacology. Male. Middle Aged. T-Lymphocytes / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. LOVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20434328.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 1UQM1K0W9X / mevastatin; 97C5T2UQ7J / Cholesterol; 9LHU78OQFD / Lovastatin
  •  go-up   go-down


35. Nagel S, Scherr M, Kel A, Hornischer K, Crawford GE, Kaufmann M, Meyer C, Drexler HG, MacLeod RA: Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1. Cancer Res; 2007 Feb 15;67(4):1461-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1.
  • In T-cell acute lymphoblastic leukemia, alternative t(5;14)(q35;q32.2) forms effect dysregulation of either TLX3 or NKX2-5 homeobox genes at 5q35 by juxtaposition with 14q32.2 breakpoints dispersed across the BCL11B downstream genomic desert.
  • We suggest that HMGA1 and PU.1 coregulate ectopic homeobox gene expression in t(5;14) T-cell acute lymphoblastic leukemia by interactions mediated at the nuclear matrix.
  • [MeSH-major] DNA-Binding Proteins / genetics. Gene Expression Regulation, Leukemic. HMGA Proteins / genetics. Homeodomain Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Oncogene Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins / genetics. Repressor Proteins / genetics. Trans-Activators / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17308084.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL11B protein, human; 0 / DNA-Binding Proteins; 0 / HMGA Proteins; 0 / Histones; 0 / Homeodomain Proteins; 0 / NKX2-5 protein, human; 0 / Oligonucleotides; 0 / Oncogene Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / Repressor Proteins; 0 / TLX3 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / proto-oncogene protein Spi-1; EC 3.1.21.1 / Deoxyribonuclease I
  •  go-up   go-down


36. Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S, Allen CG, Gale RE, Linch DC, Palomero T, Real P, Murty V, Yao X, Richards SM, Goldstone A, Rowe J, Basso G, Wiernik PH, Paietta E, Pieters R, Horstmann M, Meijerink JP, Ferrando AA: WT1 mutations in T-ALL. Blood; 2009 Jul 30;114(5):1038-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The molecular mechanisms involved in disease progression and relapse in T-cell acute lymphoblastic leukemia (T-ALL) are poorly understood.
  • Subsequent analysis showed WT1 mutations in 28 of 211 (13.2%) of pediatric and 10 of 85 (11.7%) of adult T-ALL cases.
  • Survival analysis demonstrated that WT1 mutations do not confer adverse prognosis in pediatric and adult T-ALL.
  • [MeSH-major] Genes, Wilms Tumor. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Child. Chromosome Aberrations. Clone Cells / chemistry. DNA Methylation. DNA Mutational Analysis. DNA, Neoplasm / genetics. Disease Progression. Genes, Homeobox. Humans. Kaplan-Meier Estimate. Neoplasm Proteins / chemistry. Neoplasm Proteins / genetics. Oncogenes. Polymorphism, Single Nucleotide. Prognosis. Recurrence. WT1 Proteins / chemistry. WT1 Proteins / genetics. Zinc Fingers / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6010-4 [1321431.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Hum Mol Genet. 1993 Mar;2(3):259-64 [8388765.001]
  • [Cites] Blood. 1994 May 15;83(10):2922-30 [8180387.001]
  • [Cites] Hum Mol Genet. 1995 Mar;4(3):351-8 [7795587.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2171-9 [8630376.001]
  • [Cites] Hum Mutat. 1997;9(3):209-25 [9090524.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] Eur J Haematol. 1997 May;58(5):346-9 [9222290.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2961-8 [9531607.001]
  • [Cites] Kidney Int. 1998 Jun;53(6):1512-8 [9607183.001]
  • [Cites] Blood. 2005 Jul 1;106(1):274-86 [15774621.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jan;46(1):18-25 [15929133.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1279-87 [16688224.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1212-21 [16956820.001]
  • [Cites] Leukemia. 2007 Mar;21(3):550-1; author reply 552 [17205055.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1258-66 [17443227.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9006-12 [17909001.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6838-49 [17934490.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6964-9 [18056171.001]
  • [Cites] J Exp Med. 2007 Dec 24;204(13):3059-66 [18070937.001]
  • [Cites] Leukemia. 2008 Jan;22(1):124-31 [17928886.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):83-93 [18094723.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Leukemia. 2008 Apr;22(4):762-70 [18185524.001]
  • [Cites] Nat Rev Immunol. 2008 May;8(5):380-90 [18421304.001]
  • [Cites] Blood. 2008 May 1;111(9):4668-80 [18299449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6708-13 [18458336.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] Science. 2008 Nov 28;322(5906):1377-80 [19039135.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Genome Biol. 2001;2(8):RESEARCH0032 [11532216.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1495-504 [11587205.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):416-9 [11878574.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Clin Nephrol. 1985 Dec;24(6):269-78 [3000666.001]
  • [Cites] Genomics. 1989 Nov;5(4):685-93 [2556343.001]
  • [Cites] Cell. 1990 Jun 29;61(7):1257-69 [2163761.001]
  • [Cites] FEBS Lett. 1993 Feb 8;317(1-2):39-43 [8381368.001]
  • (PMID = 19494353.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE15931
  • [Grant] United States / NCI NIH HHS / CA / CA114737; United Kingdom / Medical Research Council / / MC/ U137686856; United States / NCI NIH HHS / CA / R01 CA129382; United Kingdom / Medical Research Council / / ; United States / NCI NIH HHS / CA / CA02111; United Kingdom / Medical Research Council / / G0500389; United States / NCI NIH HHS / CA / R01CA120196; United States / NCI NIH HHS / CA / R01CA129382; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / R01 CA120196-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / WT1 Proteins
  • [Other-IDs] NLM/ PMC2721784
  •  go-up   go-down


37. Raetz EA, Perkins SL, Bhojwani D, Smock K, Philip M, Carroll WL, Min DJ: Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer; 2006 Aug;47(2):130-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
  • BACKGROUND: T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL) and are often thought to represent a spectrum of a single disease.
  • [MeSH-major] Gene Expression Profiling. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358311.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA88361
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


38. Kovac L, Bilić M, Bumber B, Topić I: Primary laryngeal manifestation in precursor T-cell acute lymphoblastic leukemia. Otolaryngol Head Neck Surg; 2008 Sep;139(3):474-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary laryngeal manifestation in precursor T-cell acute lymphoblastic leukemia.
  • [MeSH-major] Airway Obstruction / etiology. Glottis. Laryngeal Neoplasms / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Precursor Cells, T-Lymphoid. Tracheal Stenosis / etiology
  • [MeSH-minor] Adult. Comorbidity. Fatal Outcome. Female. Humans. Immunocompromised Host. Immunohistochemistry. Pseudomonas Infections / epidemiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Choking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18722237.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Lin D, Liu C, Xue M, Liu R, Jiang L, Yu X, Bao G, Deng F, Yu M, Ao J, Zhou Y, Wu D, Liu H: The role of interleukin-15 polymorphisms in adult acute lymphoblastic leukemia. PLoS One; 2010;5(10):e13626
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of interleukin-15 polymorphisms in adult acute lymphoblastic leukemia.
  • Previous studies revealed that five SNPs in IL-15, rs10519612, rs10519613, rs35964658, rs17007695 and rs17015014, were significantly associated with childhood Acute Lymphoblastic Leukemia (ALL) treatment response.
  • In adult ALL, the expression of IL-15 was also correlated with the immunophenotypes of ALL.
  • Therefore, we hypothesize that SNPs of IL-15 might also be associated with adult ALL.
  • METHODS AND FINDINGS: We genotyped the above five SNPs of IL-15 gene by PCR-RFLP assays in adult ALL case-control studies.
  • The current study included 121 adult ALL patients and 263 healthy controls.
  • Haplotype analysis revealed that haplotypes ACAC, CAGT and CCAT were significantly associated with adult B-ALL, while haplotype CCAT conferred susceptibility to T-ALL.
  • CONCLUSION: These findings suggest that IL-15 gene polymorphisms are significantly associated with ALL in adult Chinese population.
  • [MeSH-major] Interleukin-5 / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adult. Base Sequence. Case-Control Studies. DNA Primers. Female. Genotype. Haplotypes. Humans. Linkage Disequilibrium. Male. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1994 Oct 1;180(4):1395-403 [7523571.001]
  • [Cites] Cancer. 2010 Jan 15;116(2):387-92 [19924795.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3861-8 [7579354.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3327-35 [8605349.001]
  • [Cites] JAMA. 1997 Dec 10;278(22):1993-9 [9396662.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2380-5 [10090949.001]
  • [Cites] Blood. 2005 Jan 15;105(2):894-901 [15374888.001]
  • [Cites] Cell Res. 2005 Feb;15(2):97-8 [15740637.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3053-8 [15833833.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2302-10 [15976182.001]
  • [Cites] J Immunol. 2006 Jan 1;176(1):507-15 [16365444.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Oct;36(1):49-58 [10996522.001]
  • [Cites] Blood. 2001 Jan 1;97(1):14-32 [11133738.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Dec;13(6):429-39 [12401478.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74 [14762166.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jun;50(3):223-61 [15182827.001]
  • [Cites] Immunol Today. 1990 Oct;11(10):350-4 [2171545.001]
  • [Cites] Leukemia. 1992 Nov;6 Suppl 4:49-51 [1434832.001]
  • [Cites] Blood. 1993 Jul 15;82(2):576-80 [8329712.001]
  • [Cites] Science. 1994 May 13;264(5161):965-8 [8178155.001]
  • [Cites] Annu Rev Immunol. 2006;24:657-79 [16551262.001]
  • [Cites] Bioessays. 2006 Apr;28(4):362-77 [16547946.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Aug;17(4):259-80 [16815076.001]
  • [Cites] Nat Rev Immunol. 2006 Aug;6(8):595-601 [16868550.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] J Invest Dermatol. 2007 Nov;127(11):2544-51 [17554368.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4813-20 [17947730.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Science. 2008 Nov 28;322(5906):1377-80 [19039135.001]
  • [Cites] JAMA. 2009 Jan 28;301(4):393-403 [19176441.001]
  • [Cites] Cell Res. 2009 Apr;19(4):519-23 [19290020.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:593-601 [20008244.001]
  • [Cites] Blood. 2000 Jan 15;95(2):610-8 [10627470.001]
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):205-11 [10882175.001]
  • [Cites] Cancer. 2010 Mar 1;116(5):1165-76 [20101737.001]
  • [Cites] J Immunol. 1995 Jan 15;154(2):483-90 [7814861.001]
  • (PMID = 21049047.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Interleukin-5
  • [Other-IDs] NLM/ PMC2963612
  •  go-up   go-down


40. Fu MW, Mi YC, Qiu LG, Yu WJ, Lin D, Bian SG, Wang JX: [Analysis of chemotherapeutic results and prognostic factors of adult acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2008 Jul;29(7):435-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of chemotherapeutic results and prognostic factors of adult acute lymphoblastic leukemia].
  • OBJECTIVE: To explore the clinical characteristics of adult acute lymphoblastic leukemia (ALL), compare the efficacy of different induction regimens and analyze the prognostic factors.
  • METHODS: Data of 149 adult ALL patients hospitalized in our institute between June 1998 and December 2005 were retrospectively reviewed.
  • CONCLUSIONS: Most adult ALL patients are B-ALL and karyotype have more changed.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035173.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


41. Park HH, Kim M, Lee BH, Lim J, Kim Y, Lee EJ, Min WS, Kang CS, Kim WI, Shim SI, Han K: Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia. Ann Clin Lab Sci; 2006;36(1):7-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Leukemia, Myeloid / blood. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / metabolism. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Remission Induction

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501231.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


42. Lee E, Park HJ, Cho BK, Lee JY, Lee S: Leukemia cutis as early relapse of T-cell acute lymphoblastic leukemia. Int J Dermatol; 2010 Mar;49(3):335-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia cutis as early relapse of T-cell acute lymphoblastic leukemia.
  • [MeSH-major] Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20465677.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


43. Zohren F, Czibere A, Bruns I, Fenk R, Schroeder T, Gräf T, Haas R, Kobbe G: Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia. Bone Marrow Transplant; 2009 Dec;44(12):785-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
  • In this prospective study, we examined the toxicity and efficacy of an intensified conditioning regimen for treatment of patients with relapsed or high-risk acute lymphoblastic leukemia who undergo allogeneic hematopoietic stem cell transplantation.
  • Thus, conditioning with the FLAMSA-ATG-TBI regimen is a feasible and effective alternative for patients with relapsed or high-risk acute lymphoblastic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Amsacrine / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Recurrence. Risk Factors. Survival Rate. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Whole-Body Irradiation / methods

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. AMSACRINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19430496.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


44. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Gaynon PS, Camitta BM: Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood; 2007 Feb 1;109(3):926-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
  • This merger allowed analysis of clinical, biologic, and early response data predictive of event-free survival (EFS) in acute lymphoblastic leukemia (ALL) to develop a new classification system and treatment algorithm.
  • From 11 779 children (age, 1 to 21.99 years) with newly diagnosed B-precursor ALL consecutively enrolled by the CCG (December 1988 to August 1995, n=4986) and POG (January 1986 to November 1999, n=6793), we retrospectively analyzed 6238 patients (CCG, 1182; POG, 5056) with informative cytogenetic data.
  • The COG risk classification scheme is being used for division of B-precursor ALL into lower- (27%), standard- (32%), high- (37%), and very-high- (4%) risk groups based on age, white blood cell (WBC) count, cytogenetics, day-14 marrow response, and end induction minimal residual disease (MRD) by flow cytometry in COG trials.


45. Agirre X, Román-Gómez J, Jiménez-Velasco A, Garate L, Montiel-Duarte C, Navarro G, Vázquez I, Zalacain M, Calasanz MJ, Heiniger A, Torres A, Minna JD, Prósper F: ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene; 2006 Mar 23;25(13):1862-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia.
  • We have analyzed the regulation and expression of ASPP members, genes implicated in the regulation of the apoptotic function of the TP53 tumor-suppressor gene, in acute lymphoblastic leukemia (ALL).
  • Methylation was significantly higher in adult ALL vs childhood ALL (32 vs 17%, P = 0.03) and T-ALL vs B-ALL (50 vs 9%, P = 0.001).
  • [MeSH-major] Carrier Proteins / biosynthesis. Carrier Proteins / genetics. DNA Methylation. Gene Expression Regulation, Neoplastic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis Regulatory Proteins. Child. Child, Preschool. Female. Gene Expression Profiling. Genes, p53. Humans. Infant. Male. Middle Aged. Prognosis. Promoter Regions, Genetic. Recurrence. Survival

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oncogene. 2013 Feb 7;32(6):803
  • (PMID = 16314841.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Apoptosis Regulatory Proteins; 0 / Carrier Proteins; 0 / PPP1R13B protein, human
  •  go-up   go-down


46. Nishi H, Tomida C, Gotoh M, Yamagata K, Akiyama H, Shimokama T: Chronic renal failure with severe mesangiolysis in a hematopoietic stem cell transplant recipient. Ren Fail; 2006;28(6):519-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study describes a 38-year-old female patient with acute lymphoblastic leukemia treated with HSCT who developed chronic renal dysfunction after transplantation.
  • [MeSH-minor] Adult. Female. Humans. Peritoneal Dialysis. Postoperative Complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928623.001).
  • [ISSN] 0886-022X
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Smith MA: Update on developmental therapeutics for acute lymphoblastic leukemia. Curr Hematol Malig Rep; 2009 Jul;4(3):175-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on developmental therapeutics for acute lymphoblastic leukemia.
  • This is an exciting time in drug development for acute lymphoblastic leukemia (ALL).
  • Another important trend in ALL drug development is the increasing understanding at the molecular level of the genomic changes that occur in B-precursor and T-cell ALL.
  • [MeSH-major] Drug Discovery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aniline Compounds / therapeutic use. Antineoplastic Agents / therapeutic use. Child. Enzyme Inhibitors / therapeutic use. Humans. Nucleosides / therapeutic use. Sulfonamides / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2009 Jan;15(1):50-8 [19098907.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1313-9 [17613759.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14 (12 ):3716-21 [18559588.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):173-83 [12620411.001]
  • [Cites] J Immunol. 2003 Apr 15;170(8):4397-402 [12682277.001]
  • [Cites] Leukemia. 2000 Mar;14 (3):399-402 [10720133.001]
  • [Cites] Clin Cancer Res. 2009 Feb 1;15(3):832-9 [19188153.001]
  • [Cites] J Exp Med. 2008 Apr 14;205(4):751-8 [18362173.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2240-5 [17657218.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1807-14 [14615373.001]
  • [Cites] Blood. 2005 Jan 15;105(2):812-20 [15374878.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Dec;15(12):1601-13 [17107284.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3421-8 [18451170.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] Int J Cancer. 2005 May 20;115(1):98-104 [15688411.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2057-66 [17536015.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):581-7 [17457854.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2662-7 [15805263.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1516-22 [17332297.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8295-301 [19088047.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9280-90 [19010901.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] Cancer Immunol Immunother. 2006 May;55(5):503-14 [16032400.001]
  • [Cites] Cell Death Differ. 2007 May;14(5):943-51 [17205078.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1309-12 [9360930.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2300-9 [18056841.001]
  • [Cites] Int J Hematol. 2009 Jan;89(1):3-13 [19093166.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jul;58(1):13-23 [16292537.001]
  • [Cites] Blood. 2009 Jan 15;113(3):646-8 [18927438.001]
  • [Cites] Science. 2008 Aug 15;321(5891):974-7 [18703743.001]
  • [Cites] Blood. 2008 Nov 15;112(10):3982-8 [18780832.001]
  • [Cites] Blood. 2009 Jan 8;113(2):299-305 [18931344.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4572-83 [18628472.001]
  • [Cites] Cancer J. 2008 May-Jun;14 (3):154-69 [18536555.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]
  • [Cites] Br J Haematol. 2009 Mar;144(6):930-2 [19120350.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6719-29 [16061911.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):827-39 [18422996.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):47-58 [18598943.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):799-805 [17635004.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):470-80 [19129520.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4352-61 [19147785.001]
  • [Cites] Lancet. 2008 Oct 25;372(9648):1484-92 [18805579.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):37-45 [17420992.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1181-9 [18085673.001]
  • [Cites] Blood. 2008 Sep 1;112(5):2020-3 [18544682.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3704-13 [17530024.001]
  • [Cites] Curr Pharm Biotechnol. 2001 Dec;2(4):313-25 [11762413.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):321-30 [18394555.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1149-55 [16195324.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1458-65 [12714494.001]
  • (PMID = 20425431.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Nucleosides; 0 / Sulfonamides; XKJ5VVK2WD / navitoclax
  • [Number-of-references] 79
  •  go-up   go-down


48. Schnakenberg E, Mehles A, Cario G, Rehe K, Seidemann K, Schlegelberger B, Elsner HA, Welte KH, Schrappe M, Stanulla M: Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population. BMC Med Genet; 2005 May 27;6:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population.
  • Studies on the role of these polymorphisms in the susceptibility to acute lymphoblastic leukemia (ALL) led to discrepant results.
  • [MeSH-major] Genetic Predisposition to Disease / epidemiology. Genetic Predisposition to Disease / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Germany / epidemiology. Humans. Infant. Infant, Newborn. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12810-5 [10536004.001]
  • [Cites] Ann Hematol. 1999 Apr;78(4):157-62 [10348146.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4004-9 [11274424.001]
  • [Cites] Blood. 2001 May 15;97(10):3205-9 [11342450.001]
  • [Cites] Atherosclerosis. 2001 Jun;156(2):409-15 [11395038.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):616-8 [11736945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14853-8 [11742092.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5606-11 [11929966.001]
  • [Cites] Am J Hum Genet. 2002 Jul;71(1):193-7 [12058344.001]
  • [Cites] J Hum Genet. 2003;48(1):1-7 [12560871.001]
  • [Cites] Am J Epidemiol. 2003 Apr 1;157(7):571-82 [12672676.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):154-60 [12827651.001]
  • [Cites] Blood. 2004 Jan 1;103(1):252-7 [12958073.001]
  • [Cites] Haematologica. 2004 Feb;89(2):139-44 [15003888.001]
  • [Cites] Cancer Biol Ther. 2004 Jan;3(1):13-20 [14726677.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):787-94 [15159311.001]
  • [Cites] Nat Genet. 1995 May;10(1):111-3 [7647779.001]
  • [Cites] Circulation. 1997 Oct 21;96(8):2573-7 [9355896.001]
  • [Cites] Am J Hum Genet. 1998 May;62(5):1044-51 [9545395.001]
  • [Cites] Mol Genet Metab. 1998 Jul;64(3):169-72 [9719624.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 15921520.001).
  • [ISSN] 1471-2350
  • [Journal-full-title] BMC medical genetics
  • [ISO-abbreviation] BMC Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  • [Other-IDs] NLM/ PMC1164414
  •  go-up   go-down


49. Li YQ, Wu XL, Yang LJ, Chen SH, Geng SX, Przybylski G, Schmidt CA: [Thymic recent output function in patients with B-cell lymphocytic malignancies]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct;15(5):1023-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Quantitative analysis of T-cell receptor rearrangement excision circles (TRECs) in DNA of peripheral blood mononuclear cells from 61 cases of B-cell lymphocytic malignancy (including 20 cases of adult B-ALL, 6 case of childhood B-ALL, 4 cases of B-CLL, 17 cases of B-NHL and 14 cases of MM) were preformed by real-time PCR (TaqMan), and TREC-level was detected according to the number of CD3-positive cells.
  • The mean value of TRECs was 0.53 +/- 1.52 copies/1000 PBMNC and 2.01 +/- 3.93 copies/1000 CD3+ cells in adult B-ALL (p = 0.0005, p = 0.0123), 0.11 +/- 0.15 copies/1000 PBMNC and 0.23 +/- 0.27 copies/1000 CD3+ cells in B-CLL (p = 0.0015, p = 0.0381), 0.71 +/- 1.34 copies/1000 PBMNC in B-NHL (p = 0.0017), 0.53 +/- 0.90 copies/1000 PBMNC in MM patients (p = 0.0018), as compared with 3.76 +/- 3.42 copies/1000 PBMNC and 5.87 +/- 4.96 copies/1000 CD3+ cells in normal individuals, the TREC level was significantly decreased in all groups of B-cell lymphocytic malignancy, as well as in ALL-CR group.
  • However, the TREC level in childhood B-ALL was significant higher than those in adult B-ALL group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956683.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


50. Sulis ML, Williams O, Palomero T, Tosello V, Pallikuppam S, Real PJ, Barnes K, Zuurbier L, Meijerink JP, Ferrando AA: NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood; 2008 Aug 1;112(3):733-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heterodimerization domain (HD) mutations in NOTCH1 induce ligand-independent activation of the receptor and contribute to the pathogenesis of one-third of human T-cell lymphoblastic leukemias (T-ALLs).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Immunol. 2000 Apr;12(2):166-72 [10712939.001]
  • [Cites] Annu Rev Pathol. 2008;3:587-613 [18039126.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):197-206 [10882062.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):207-16 [10882063.001]
  • [Cites] Immunity. 2001 Mar;14(3):253-64 [11290335.001]
  • [Cites] J Exp Med. 2001 Oct 1;194(7):991-1002 [11581320.001]
  • [Cites] Immunity. 2002 Jun;16(6):869-79 [12121668.001]
  • [Cites] J Immunol. 2002 Aug 15;169(4):1817-21 [12165504.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):203-5 [12676578.001]
  • [Cites] Semin Immunol. 2003 Apr;15(2):69-79 [12681943.001]
  • [Cites] J Exp Med. 2004 Aug 16;200(4):469-79 [15314075.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Cell. 1996 Nov 1;87(3):483-92 [8898201.001]
  • [Cites] Cell. 1997 Mar 21;88(6):833-43 [9118226.001]
  • [Cites] Development. 1997 Dec;124(23):4759-67 [9428412.001]
  • [Cites] Genes Dev. 1998 Jun 15;12(12):1751-62 [9637676.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8108-12 [9653148.001]
  • [Cites] Science. 1999 Jan 1;283(5398):91-4 [9872749.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):522-5 [10206646.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Immunity. 1999 Sep;11(3):299-308 [10514008.001]
  • [Cites] Nat Immunol. 2005 Mar;6(3):314-22 [15665828.001]
  • [Cites] Cell. 2005 Aug 12;122(3):435-47 [16096062.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1279-87 [16688224.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Nat Struct Mol Biol. 2007 Apr;14(4):295-300 [17401372.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D25-30 [18073190.001]
  • [CommentIn] Blood. 2008 Aug 1;112(3):457-8 [18650457.001]
  • (PMID = 18411416.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA120196-03; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / CA120196; United States / NCI NIH HHS / CA / R01 CA120196-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, Notch1; EC 3.4.- / Amyloid Precursor Protein Secretases
  • [Other-IDs] NLM/ PMC2481531
  •  go-up   go-down


51. La Rosée P, Holm-Eriksen S, Konig H, Härtel N, Ernst T, Debatin J, Mueller MC, Erben P, Binckebanck A, Wunderle L, Shou Y, Dugan M, Hehlmann R, Ottmann OG, Hochhaus A: Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. Haematologica; 2008 May;93(5):765-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
  • We report a biomarker sub-study of the international phase I clinical trial of nilotinib (AMN107) using the established pCRKL assay in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.
  • Substantial differences between peripheral blood baseline pCRKL/CRKL ratios were observed when comparing chronic myeloid leukemia with Ph+ acute lymphoblastic leukemia.
  • Finally, rapid BCR-ABL-reactivation shortly after starting nilotinib treatment was seen in acute lymphoblastic leukemia patients with progressive disease carrying the P-loop mutations Y253H, E255K, or mutation T315I.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / chemistry. Antineoplastic Agents / pharmacology. Fusion Proteins, bcr-abl / metabolism. Gene Expression Regulation, Leukemic. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Nuclear Proteins / chemistry. Piperazines / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / pharmacology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Benzamides. Female. Humans. Imatinib Mesylate. Male. Middle Aged


52. Iwata Y, Wada T, Uchiyama A, Miwa A, Nakaya I, Tohyama T, Yamada Y, Kurokawa T, Yoshida T, Ohta S, Yokoyama H, Iida H: Remission of IgA nephropathy after allogeneic peripheral blood stem cell transplantation followed by immunosuppression for acute lymphocytic leukemia. Intern Med; 2006;45(22):1291-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Glomerulonephritis, IGA / complications. Glomerulonephritis, IGA / pathology. Immunosuppression. Peripheral Blood Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adult. Humans. Kidney / pathology. Male. Remission Induction

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17170503.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


53. Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, Lamb LS: Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant; 2007 Jun;39(12):751-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is an eight-year follow-up to our previous study showing a survival advantage to patients with an increased gammadelta T cells following ASCT. gammadelta T cell levels were collected prospectively in 153 patients (acute lymphoblastic leukemia (ALL) n = 77; acute myelogenous leukemia (AML) n = 76) undergoing partially mismatched related donor ASCT.
  • [MeSH-major] Bone Marrow Transplantation. Histocompatibility Testing. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Receptors, Antigen, T-Cell, gamma-delta / metabolism
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Graft vs Host Disease / mortality. Humans. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Prospective Studies. Recurrence. Tissue Donors. Transplantation, Homologous


54. Oyekunle AA, Kröger N, Zabelina T, Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander AR: Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant; 2006 Jan;37(1):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined retrospectively 44 patients with refractory acute leukemia (acute myeloid leukemia (AML)/acute lymphoblastic leukemia=25/19) who underwent allogeneic transplantation at our center between 11/1990 and 04/2004.
  • [MeSH-major] Blast Crisis / therapy. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Busulfan / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Myeloablative Agonists / administration & dosage. Retrospective Studies. Transplantation, Homologous. Whole-Body Irradiation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258531.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


55. Piccaluga PP, Malagola M, Rondoni M, Ottaviani E, Testoni N, Laterza C, Visani G, Pileri SA, Martinelli G, Baccarani M: Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. Leuk Lymphoma; 2006 Mar;47(3):469-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation.
  • The (1;19)(q23;p13) translocation, leading to the production of the E2A/PBX1 fusion transcript, is one of the most common translocations in pediatric B-lineage acute lymphoblastic leukemia (ALL).
  • Only few data are available concerning t(1;19)(q23;p13) in adult ALL.
  • We describe three cases of adult ALL carrying the t(1;19)(q23;p13), who were all characterized by an aggressive clinical course and short survival, and discuss the molecular features of the disease as recently identified by gene expression profiling.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Translocation, Genetic
  • [MeSH-minor] Adult. Bone Marrow Transplantation. Cytogenetic Analysis. Fatal Outcome. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Treatment Failure

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396770.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


56. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR: Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood; 2008 Mar 01;111(5):2563-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.
  • We examined the prognostic impact of cytogenetics on the outcome of 200 acute lymphoblastic leukemia (ALL) patients 15 to 65 years of age enrolled in Southwest Oncology Group (SWOG)-9400 study.
  • After accounting for the variation among karyotype groups, age was not a significant prognostic factor for OS or RFS, highlighting cytogenetics as the most important prognostic factor in adult ALL.
  • [MeSH-major] Cytogenetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Humans. Karyotyping. Male. Middle Aged. Ploidies. Recurrence. Remission Induction. Risk Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Oncogene. 2007 Jun 21;26(29):4306-18 [17237825.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1536-43 [11861265.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1337-54 [14508819.001]
  • [Cites] Leuk Lymphoma. 2003 Dec;44(12):2039-53 [14959846.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2444-51 [15039281.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):606-13 [1548523.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1316-23 [1381244.001]
  • [Cites] Leukemia. 1993 Jul;7(7):1000-4 [7686600.001]
  • [Cites] Br J Haematol. 1995 Sep;91(1):93-100 [7577660.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):601-10 [9054669.001]
  • [Cites] Leukemia. 1998 Apr;12(4):463-73 [9557602.001]
  • [Cites] Blood. 1999 Jan 1;93(1):315-20 [9864176.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] Haematologica. 2005 Sep;90(9):1179-85 [16154840.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Genet Med. 2006 Jan;8(1):16-23 [16418595.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1496-510 [16826225.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2002-7 [16990785.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3080-3 [17170128.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 18156492.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00002665
  • [Grant] United States / NCI NIH HHS / CA / CA 35176; United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / CA 63844; United States / NCI NIH HHS / CA / CA 74647; United States / NCI NIH HHS / CA / CA 38926; United States / NCI NIH HHS / CA / N01 CA035176; United States / NCI NIH HHS / CA / CA 20319; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / U10 CA063845; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA035192; United States / NCI NIH HHS / CA / CA 35119; United States / NCI NIH HHS / CA / CA 33572; United States / NCI NIH HHS / CA / CA 52654; United States / NCI NIH HHS / CA / U10 CA014028; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / CA 46441; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / CA 63845; United States / NCI NIH HHS / CA / U10 CA074647; United States / NCI NIH HHS / CA / CA 46368; United States / NCI NIH HHS / CA / CA 35178; United States / NCI NIH HHS / CA / CA 04919; United States / NCI NIH HHS / CA / CA 35090; United States / NCI NIH HHS / CA / N01 CA063844; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / U10 CA035178; United States / NCI NIH HHS / CA / CA 35431; United States / NCI NIH HHS / CA / CA 35192; United States / NCI NIH HHS / CA / U10 CA045450; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA 32102; United States / NCI NIH HHS / CA / N01 CA035178; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA045377; United States / NCI NIH HHS / CA / U10 CA058882; United States / NCI NIH HHS / CA / CA 67575; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / CA 45450; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / CA 42777; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / CA 58882; United States / NCI NIH HHS / CA / CA 30206; United States / NCI NIH HHS / CA / U10 CA035176; United States / NCI NIH HHS / CA / P01 CA030206; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / CA 14028; United States / NCI NIH HHS / CA / U10 CA063844; United States / NCI NIH HHS / CA / CA 45377; United States / NCI NIH HHS / CA / CA 35261; United States / NCI NIH HHS / CA / CA 46282
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2254550
  •  go-up   go-down


57. Haining WN, Cardoso AA, Keczkemethy HL, Fleming M, Neuberg D, DeAngelo DJ, Stone RM, Galinsky I, Silverman LB, Sallan SE, Nadler LM, Guinan EC: Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol; 2005 Mar;33(3):286-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.
  • OBJECTIVES: We and others have shown that B cell precursor acute lymphoblastic leukemia cells (ALL) stimulated with CD40 ligand become efficient antigen-presenting cells (APC) capable of expanding autologous, tumor-specific T cells from patients.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Immunotherapy, Adoptive. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antigen-Presenting Cells / immunology. Antigens, CD40 / immunology. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Secondary Prevention. T-Lymphocytes / immunology. T-Lymphocytes / transplantation. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15730852.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / K08HL72750; United States / NCI NIH HHS / CA / P01CA68484
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Cancer Vaccines
  •  go-up   go-down


58. Imataki O, Ohnishi H, Yamaoka G, Arai T, Kitanaka A, Kubota Y, Ishida T, Tanaka T: Marked increase of normal blast morphologically mimicking leukemic clone in acute lymphoblastic leukemia patient following G-CSF therapy. Int J Hematol; 2008 Nov;88(4):468-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marked increase of normal blast morphologically mimicking leukemic clone in acute lymphoblastic leukemia patient following G-CSF therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphocyte Activation / drug effects. Lymphocytes / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Cytarabine / administration & dosage. Female. Humans. Methotrexate / administration & dosage. Recovery of Function / drug effects. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lab Haematol. 2004 Oct;26(5):359-62 [15485468.001]
  • [Cites] Blood. 1993 Jan 15;81(2):281-92 [8422455.001]
  • [Cites] Am J Hematol. 1996 Jun;52(2):123-4 [8638638.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3485-6 [7685207.001]
  • [Cites] Clin Lab Haematol. 1998 Feb;20(1):49-51 [9681211.001]
  • [Cites] Acta Paediatr Jpn. 1995 Feb;37(1):78-80 [7538724.001]
  • (PMID = 18839272.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


59. Wu YJ, Li JY, Zhu MQ, Song JH, Zheng WJ: [Application of a four antibody (cMPO/cCD79aalpha/cCD3/CD45) combination to the diagnosis of acute leukemia expressing cross-lineage antigens]. Zhonghua Xue Ye Xue Za Zhi; 2006 Jul;27(7):449-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Flow cytometric immunophenotyping using intracellular antibody combination (cMPO/cCD79alpha/cCD3/CD45) was performed additionally in 60 patients who expressed cross-lineage antigens from 269 previously untreated adult AL.
  • RESULTS: Fifty-four of 269 previously untreated adult AL patients who expressed only one kind of intracellular antigen were diagnosed as cross-lineage AL, the percentage of cross-lineage AL in T cell acute lymphoblastic leukemia (T-ALL), B-ALL and acute myeloid leukemia (AML) was 28.6%, 43.6% and 13.4%, respectively.
  • [MeSH-major] Antibodies, Monoclonal. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD3 / immunology. Antigens, CD45 / immunology. Antigens, CD79 / immunology. Antigens, Surface / immunology. Cross Reactions. Female. Flow Cytometry. Humans. Immunophenotyping. Male. Middle Aged. Sensitivity and Specificity

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147246.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD3; 0 / Antigens, CD79; 0 / Antigens, Surface; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


60. Staal FJ, van Dongen JJ, Langerak AW: Novel insights into the development of T-cell acute lymphoblastic leukemia. Curr Hematol Malig Rep; 2007 Jul;2(3):176-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel insights into the development of T-cell acute lymphoblastic leukemia.
  • T-cell acute lymphoblastic leukemia (T-ALL) results from malignant transformation of immature cells of the T-cell lineage.
  • [MeSH-major] Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Adult. Animals. Antigens, Differentiation, T-Lymphocyte / analysis. Antigens, Neoplasm / analysis. Antineoplastic Agents / pharmacology. Cell Transformation, Neoplastic. Child. Drug Delivery Systems. Gene Expression Profiling. Gene Expression Regulation, Developmental. Gene Expression Regulation, Leukemic. Humans. Lymphopoiesis / physiology. Mice. Oncogene Proteins, Fusion / antagonists & inhibitors. Oncogene Proteins, Fusion / biosynthesis. Oncogene Proteins, Fusion / genetics. Oncogenes. Receptors, Antigen, T-Cell / genetics. Receptors, Notch / physiology. T-Lymphocytes / immunology. T-Lymphocytes / pathology. Thymus Gland / pathology. Translocation, Genetic. Wnt Proteins / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Immunol. 2006 Mar;27(3):125-31 [16473042.001]
  • [Cites] J Exp Med. 2001 Jul 2;194(1):99-106 [11435476.001]
  • [Cites] Bioessays. 1997 Jul;19(7):607-13 [9230693.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):21-30 [15630426.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12682-7 [15314234.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Chem Biol. 2007 Feb;14(2):209-19 [17317574.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12876-82 [14709552.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Curr Opin Immunol. 2003 Apr;15(2):204-8 [12633671.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3462-9 [17148581.001]
  • [Cites] Science. 1986 Nov 21;234(4779):982-5 [3490692.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Leukemia. 2007 Apr;21(4):754-63 [17268520.001]
  • [Cites] Leukemia. 2006 Nov;20(11):1967-77 [16990763.001]
  • [Cites] Nat Immunol. 2004 Mar;5(3):247-53 [14985712.001]
  • [Cites] Leukemia. 2005 Feb;19(2):201-8 [15668700.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2693-703 [12446444.001]
  • [Cites] Nature. 2006 Sep 21;443(7109):E5; discussion E6-7 [16988660.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3322-6 [16492759.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6265-73 [9343387.001]
  • [Cites] J Allergy Clin Immunol. 2005 Apr;115(4):834-40 [15806007.001]
  • [Cites] Leukemia. 2006 Nov;20(11):1963-6 [17008890.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3788-93 [11891328.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1245-53 [16673019.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3313-20 [16368887.001]
  • [Cites] J Exp Med. 2005 Jun 6;201(11):1715-23 [15928199.001]
  • [Cites] Leukemia. 2005 Nov;19(11):1948-57 [16107895.001]
  • [Cites] Blood. 2007 Jul 1;110(1):388-92 [17360939.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1197-205 [16688226.001]
  • [Cites] EMBO J. 1998 Aug 17;17(16):4594-605 [9707419.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5463-72 [17317856.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Eur J Immunol. 2001 Jan;31(1):285-93 [11265645.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):587-96 [15193261.001]
  • [Cites] Blood. 2005 Jul 1;106(1):274-86 [15774621.001]
  • [Cites] Nat Immunol. 2001 Mar;2(3):235-41 [11224523.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6068-73 [15827121.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Oncogene. 1996 Aug 1;13(3):617-24 [8760303.001]
  • [Cites] Annu Rev Immunol. 2006;24:287-320 [16551251.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):380-9 [11888077.001]
  • [Cites] Leukemia. 2007 Mar;21(3):462-71 [17252014.001]
  • (PMID = 20425367.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, Notch; 0 / Wnt Proteins
  • [Number-of-references] 50
  •  go-up   go-down


61. Capdeville R, Krahnke T, Hatfield A, Ford JM, Van Hoomissen I, Gathmann I: Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias. Ann Oncol; 2008 Jul;19(7):1320-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: In total, 7380 patients with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia failing prior therapies were enrolled in 106 centers in 34 countries.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18344535.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


62. Arellano ML, Langston A, Winton E, Flowers CR, Waller EK: Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant; 2007 Jan;13(1):116-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed 310 patients with acute leukemia who received allogeneic hematopoietic progenitor cell transplants from HLA-matched donors between 1982 and 2005 (229 with acute myelogenous leukemia, 81 with acute lymphoblastic leukemia).
  • One hundred of 310 patients (32%) with acute leukemia relapsed after transplantation, including 28 of 81 patients (35%) with acute lymphoblastic leukemia and 72 of 229 (31%) with acute myelogenous leukemia at a median of 136 days after transplantation.
  • [MeSH-major] Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cell Transplantation. Interferon-alpha / therapeutic use. Leukemia, Myeloid, Acute / therapy. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Immunotherapy / methods. Kaplan-Meier Estimate. Male. Middle Aged. Mortality. Prognosis. Retrospective Studies. Salvage Therapy / methods. Transplantation, Homologous / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222760.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


63. Malbasa T, Kodish E, Santacroce SJ: Adolescent adherence to oral therapy for leukemia: a focus group study. J Pediatr Oncol Nurs; 2007 May-Jun;24(3):139-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This secondary qualitative analysis of extant focus group data was performed to develop an understanding of suboptimal adherence to 6-mercaptopurine therapy in adolescents with acute lymphoblastic leukemia.
  • Six participants, aged 16 to 23 years at the time of data collection, were interviewed about their adherence to oral maintenance chemotherapy during their treatment for acute lymphoblastic leukemia.
  • [MeSH-major] 6-Mercaptopurine / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Patient Compliance / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Administration, Oral. Adolescent. Adolescent Behavior / psychology. Adolescent Development. Adult. Family / psychology. Female. Focus Groups. Hospitals, University. Humans. Male. Nursing Methodology Research. Ohio. Patient Education as Topic. Peer Group. Pilot Projects. Psychology, Adolescent. Qualitative Research. Social Support. Surveys and Questionnaires. Thinking

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17475980.001).
  • [ISSN] 1043-4542
  • [Journal-full-title] Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses
  • [ISO-abbreviation] J Pediatr Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine
  •  go-up   go-down


64. Gué M, Sun JS, Boudier T: Simultaneous localization of MLL, AF4 and ENL genes in interphase nuclei by 3D-FISH: MLL translocation revisited. BMC Cancer; 2006;6:20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Using triple labeling 3D FISH experiments, we have determined the relative positions of MLL, AF4 and ENL genes, in two lymphoblastic and two myeloid human cell lines.
  • [MeSH-minor] Adolescent. Adult. Cell Line, Transformed / chemistry. Cell Line, Transformed / ultrastructure. Cell Line, Tumor / chemistry. Cell Line, Tumor / ultrastructure. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 11 / ultrastructure. Chromosomes, Human, Pair 19 / genetics. Chromosomes, Human, Pair 19 / ultrastructure. Chromosomes, Human, Pair 4 / genetics. Chromosomes, Human, Pair 4 / ultrastructure. HL-60 Cells / chemistry. HL-60 Cells / ultrastructure. Herpesvirus 4, Human. Histone-Lysine N-Methyltransferase. Humans. Interphase. Leukemia, Monocytic, Acute / genetics. Leukemia, Monocytic, Acute / pathology. Male. Models, Genetic. Multiple Myeloma / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chromosoma. 1999 Dec;108(7):426-35 [10654081.001]
  • [Cites] Cytometry A. 2005 Sep;67(1):18-26 [16082715.001]
  • [Cites] Leukemia. 2000 Mar;14(3):513-7 [10720153.001]
  • [Cites] Genes Chromosomes Cancer. 2000 May;28(1):14-22 [10738298.001]
  • [Cites] Science. 2000 Oct 6;290(5489):138-41 [11021799.001]
  • [Cites] Leukemia. 2001 Jun;15(6):987-9 [11417488.001]
  • [Cites] Trends Cell Biol. 2002 Sep;12(9):425-32 [12220863.001]
  • [Cites] Leukemia. 2003 Feb;17(2):416-26 [12592342.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):287-91 [12808455.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):639-49 [12951583.001]
  • [Cites] Science. 2004 Jan 2;303(5654):92-5 [14704429.001]
  • [Cites] Genome Biol. 2004;5(7):R44 [15239829.001]
  • [Cites] Exp Cell Res. 1995 Jul;219(1):159-68 [7628532.001]
  • [Cites] Leukemia. 1998 May;12(5):779-87 [9593281.001]
  • [Cites] Leukemia. 1998 May;12(5):805-10 [9593285.001]
  • [Cites] Leukemia. 1998 May;12(5):840-4 [9593290.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1197-207 [9949162.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2004 Nov;50(7):805-7 [15672464.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1608-15 [10688815.001]
  • (PMID = 16433901.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / MLLT1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 150826-18-9 / AFF1 protein, human; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Other-IDs] NLM/ PMC1388228
  •  go-up   go-down


65. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ: Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood; 2007 Jul 1;110(1):278-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia.
  • Constitutive Notch activation is required for the proliferation of a subgroup of T-cell acute lymphoblastic leukemia (T-ALL).
  • [MeSH-major] Amyloid Precursor Protein Secretases / physiology. Leukemia-Lymphoma, Adult T-Cell / metabolism. Protein Kinases / metabolism. Proto-Oncogene Proteins c-myc / metabolism. Receptors, Notch / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Feb 1;19(3):434-44 [10654941.001]
  • [Cites] Nat Immunol. 2005 Sep;6(9):881-8 [16056227.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Science. 2001 Nov 30;294(5548):1942-5 [11729323.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3788-93 [11891328.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):655-64 [12509463.001]
  • [Cites] EMBO Rep. 2003 Nov;4(11):1067-72 [14566327.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):343-8 [14667501.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):209-20 [16354692.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1936-40 [16449385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1941-6 [16449386.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2223-33 [16291593.001]
  • [Cites] Cell. 2006 Mar 10;124(5):973-83 [16530044.001]
  • [Cites] Blood. 2006 May 15;107(10):4115-21 [16449526.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9262-7 [16751266.001]
  • [Cites] BMC Bioinformatics. 2006;7:192 [16600027.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):729-34 [16915295.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8022-31 [16954387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):200-16 [14673156.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2937-44 [14583609.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3151-71 [15094765.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):48-54 [15108805.001]
  • [Cites] Nat Med. 2004 May;10(5):484-6 [15098029.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Cell Biol. 2004 Oct 25;167(2):215-21 [15492044.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Nature. 1995 Sep 28;377(6547):355-8 [7566092.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2283-91 [8642337.001]
  • [Cites] J Biol Chem. 1998 Jul 24;273(30):18984-91 [9668078.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Biochemistry. 1999 Aug 10;38(32):10344-51 [10441128.001]
  • [Cites] Immunity. 1999 Sep;11(3):299-308 [10514008.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1390-6 [15558056.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):992-1000 [15592506.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):605-11 [15931213.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3337-48 [10880446.001]
  • (PMID = 17363738.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MAML1 protein, human; 0 / MYC protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptors, Notch; 0 / Trans-Activators; 0 / Transcription Factors; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 3.4.- / Amyloid Precursor Protein Secretases
  • [Other-IDs] NLM/ PMC1896117
  •  go-up   go-down


66. Suggs JL, Cruse JM, Lewis RE: Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias. Exp Mol Pathol; 2007 Dec;83(3):471-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias.
  • The World Health Organization (WHO) characterization of the immunophenotype of precursor B-cell acute lymphoblastic leukemia (pre-B ALL) includes the possible expression of myeloid cluster of differentiation (CD) markers CD13 and CD33.
  • In precursor T-cell acute lymphoblastic leukemia (pre-T ALL), myeloid markers CD13 and CD33 are frequent while CD117 is rare.
  • [MeSH-major] Biomarkers / metabolism. Leukemia, B-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism. Precursor Cells, B-Lymphoid / metabolism
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / metabolism. Child. Humans. Male. World Health Organization

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963747.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers
  •  go-up   go-down


67. Oriol A, Vives S, Hernández-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardó F, Bueno J, Grande C, del Potro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM, Programa Español de Tratamiento en Hematologia Group: Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica; 2010 Apr;95(4):589-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.
  • BACKGROUND: About one half of adults with acute lymphoblastic leukemia are not cured of the disease and ultimately die.
  • The objective of this study was to explore the factors influencing the outcome of adult patients with relapsed acute lymphoblastic leukemia.
  • DESIGN AND METHODS: We analyzed the characteristics, the outcome and the prognostic factors for survival after first relapse in a series of 263 adult patients with acute lymphoblastic leukemia (excluding those with mature B-cell acute lymphoblastic leukemia) prospectively enrolled in four consecutive risk-adapted PETHEMA trials.
  • CONCLUSIONS: The prognosis of adult patients with acute lymphoblastic leukemia who relapse is poor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasm Recurrence, Local / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Remission Induction. Risk Factors. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Andalusian Health Repository. Full Text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix [11147225.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1843-9 [18398150.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Cancer Treat Rev. 2003 Feb;29(1):3-10 [12633575.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Biometrics. 1973 Sep;29(3):579-84 [4793138.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):896-903 [9217194.001]
  • [Cites] Leuk Lymphoma. 1997 May;25(5-6):579-83 [9250830.001]
  • [Cites] Haematologica. 1998 Mar;83(3):222-30 [9573676.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1216-30 [10506707.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1509-16 [16034462.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1346-56 [16219571.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):748-56 [16470520.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] Eur J Haematol. 2007 Feb;78(2):102-10 [17087744.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):163-205 [11253606.001]
  • (PMID = 20145276.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2857188
  • [Investigator] Ribera JM; Oriol A; Vives S; Feliu E; Hernández-Rivas JM; San Miguel JF; Tormo M; Terol MJ; Heras MI; Bernal T; Martínez-Revuelta E; Fuster J; Esteve J; Calvo C; Carboné A; Brunet S; Sierra J; Bergua JL; Marín J; Egurbide I; Sánchez J; García-Boyero R; Pérez de Oteyza J; Sarrà J; Bueno J; Ortega JJ; Bastida MP; Olivé T; Pérez-Hurtado JM; Parody R; González-Valentín ME; Rivas C; Fernández-Abellán P; Sanz MA; Moscardó F; Montesinos P; del Potro E; Díaz-Mediavilla J; Guinea JM; Guardia R; Martí JM; Vall-llobera F; Poderós C; Queizán JA; Martínez J; Bethencourt C; Maldonado J; Martín-Reina V; Gil JL; Moreno MJ; Ortega-Rivas F; Rodríguez JA; Moro MJ; Molinés A; Lodos V; Macià J; Novo A; Besalduch J; Pedro C; Abella E; Deben G; Casanova F; Gámez F; Alcalá A; Arias J; León P; Ares A; Llorente A; Atutxa K; Hernández-Nieto L; Díaz-Morfa G; Vivancos P; Rodríguez-Villa A; Bello JL; Carbonell F; Orts M; Fernández-Calvo J; Borrego D; Grande C
  •  go-up   go-down


68. Ek T, Mellander L, Andersson B, Abrahamsson J: Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group. Pediatr Blood Cancer; 2005 May;44(5):461-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group.
  • [MeSH-major] Immune System / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Regeneration. Vaccination
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / analysis. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. B-Lymphocytes / cytology. B-Lymphocytes / immunology. Case-Control Studies. Child. Child, Preschool. Cross-Sectional Studies. Humans. Immunoglobulins / blood. Immunosuppression / methods. Killer Cells, Natural / cytology. Killer Cells, Natural / immunology. Lymphocyte Subsets / cytology. T-Lymphocytes / cytology. T-Lymphocytes / immunology. Time Factors


69. Nachman J: Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol; 2005 Jul;130(2):166-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia.
  • Young adult patients with acute lymphoblastic leukaemia (ALL) represent a unique epidemiologic subgroup in that therapy may be provided by either adult or paediatric oncologists.
  • There seem to be no differences in presenting clinical features, immunophenotypic characteristics, or cytogenetic abnormalities for young adult ALL patients treated on paediatric or adult protocols with the exception of median age (16-paediatric trials versus 19-adult trials).
  • Compared with patients 1-9 years, young adult ALL patients have a lower incidence of favourable cytogenetics t(12;.
  • Compared with patients >30 years, young adult ALL patients have a significantly lower incidence of the t(9; 22).
  • In multiple studies, there is a consistent, large event-free survival and survival advantage for young adult patients treated on paediatric versus adult protocols.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Aberrations. Humans. Prognosis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029445.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 29
  •  go-up   go-down


70. Vitale A, Guarini A, Chiaretti S, Foà R: The changing scene of adult acute lymphoblastic leukemia. Curr Opin Oncol; 2006 Nov;18(6):652-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The changing scene of adult acute lymphoblastic leukemia.
  • PURPOSE OF REVIEW: The review focuses on the most recent advances in the diagnostic and prognostic work-up of adult acute lymphoblastic leukemia (ALL) and its implications in the clinical management of the disease.
  • SUMMARY: Recent biologic advancements are progressively realising the possibility of designing targeted and individualized therapeutic strategies according to the more refined, molecularly defined features of leukemic cells and the presence or absence of residual disease in adult ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Neoplasm, Residual / diagnosis. Neoplasm, Residual / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988590.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 104
  •  go-up   go-down


71. Czibere A, Bruns I, Graef T, Fenk R, Zohren F, Safaian N, Mueller M, Haas R, Kobbe G: Treatment of severe hemorrhagic cystitis after allogeneic stem cell transplantation with palifermin, a recombinant human keratinocyte growth factor. Biol Blood Marrow Transplant; 2007 Jul;13(7):872-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Cystitis / drug therapy. Fibroblast Growth Factor 7 / administration & dosage. Hemorrhage / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Humans. Male. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580267.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 126469-10-1 / Fibroblast Growth Factor 7
  •  go-up   go-down


72. Gumy-Pause F, Wacker P, Maillet P, Betts DR, Sappino AP: ATM variants and predisposition to childhood T-lineage acute lymphoblastic leukaemia. Leukemia; 2006 Mar;20(3):526-7; author reply 527
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ATM variants and predisposition to childhood T-lineage acute lymphoblastic leukaemia.
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA-Binding Proteins / genetics. Genetic Predisposition to Disease. Leukemia-Lymphoma, Adult T-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Proteins / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leukemia. 2005 Nov;19(11):1887-95 [16167060.001]
  • (PMID = 16408093.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comment; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


73. Di Bona E, Pogliani E, Rossi G, Lerede T, D'Emilio A, Vespignani M, Rodeghiero F, Barbui T, Bassan R: Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients. Leuk Lymphoma; 2005 Jun;46(6):879-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients.
  • Idarubicin-based induction programs in acute lymphoblastic leukemia (ALL) account for 75?
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Methotrexate / administration & dosage. Mitoxantrone / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation. Female. Granulocyte Colony-Stimulating Factor / metabolism. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019533.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; BZ114NVM5P / Mitoxantrone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


74. Aisa Y, Mori T, Tanikawa A, Takae Y, Kato J, Ikeda Y, Okamoto S: Demodicidosis as a cause of facial eruption developing early after allogeneic hematopoietic stem cell transplantation. Transpl Int; 2008 Dec;21(12):1192-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Animals. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Middle Aged. Mite Infestations / diagnosis. Mites. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Transplantation Conditioning

  • Genetic Alliance. consumer health - Demodicidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Rashes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783387.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


75. Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Deschner J, Frühwald MC, Dassmann S, Pham TH, Roth J, Foell D: S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. Arthritis Rheum; 2008 Dec;58(12):3924-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Serum samples were obtained from 45 healthy control subjects and from 240 patients (60 with systemic-onset JIA, 17 with familial Mediterranean fever [FMF], 18 with neonatal-onset multisystem inflammatory disease [NOMID], 17 with Muckle-Wells syndrome [MWS], 40 with acute lymphoblastic leukemia [ALL], 5 with acute myeloblastic leukemia [AML], and 83 with systemic infections).
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Familial Mediterranean Fever / blood. Familial Mediterranean Fever / diagnosis. Familial Mediterranean Fever / immunology. Female. Granulocytes / immunology. Humans. Infant. Infection / blood. Infection / diagnosis. Infection / immunology. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. S100A12 Protein. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Arthritis, Juvenile.
  • MedlinePlus Health Information. consumer health - Juvenile Arthritis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2001 May;107(9):1127-35 [11342576.001]
  • [Cites] J Exp Med. 2007 Sep 3;204(9):2131-44 [17724127.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):949-55 [11581294.001]
  • [Cites] N Engl J Med. 2001 Dec 13;345(24):1748-57 [11742050.001]
  • [Cites] Arthritis Rheum. 2002 Aug15;47(4):429-33 [12209491.001]
  • [Cites] Lancet. 2003 Apr 12;361(9365):1270-2 [12699958.001]
  • [Cites] Gut. 2003 Jun;52(6):847-53 [12740341.001]
  • [Cites] Rheumatology (Oxford). 2003 Nov;42(11):1383-9 [12832707.001]
  • [Cites] J Rheumatol. 2004 Feb;31(2):390-2 [14760812.001]
  • [Cites] Arthritis Rheum. 2004 Apr;50(4):1286-95 [15077313.001]
  • [Cites] J Pathol. 2004 Nov;204(3):311-6 [15476267.001]
  • [Cites] Curr Clin Top Infect Dis. 1991;11:35-51 [1651090.001]
  • [Cites] Arthritis Rheum. 1997 Jul;40(7):1202-9 [9214419.001]
  • [Cites] Lancet. 1997 Aug 23;350(9077):575-80 [9284789.001]
  • [Cites] Ann Rheum Dis. 1998 Jan;57(1):38-41 [9536821.001]
  • [Cites] Br J Rheumatol. 1998 May;37(5):562-9 [9651086.001]
  • [Cites] Clin Rheumatol. 1998;17(3):258-60 [9694067.001]
  • [Cites] Lancet. 1998 Mar 28;351(9107):969-73 [9734957.001]
  • [Cites] Curr Opin Rheumatol. 1998 Sep;10(5):459-67 [9746862.001]
  • [Cites] Baillieres Clin Rheumatol. 1998 May;12(2):245-71 [9890097.001]
  • [Cites] Cell. 1999 Jun 25;97(7):889-901 [10399917.001]
  • [Cites] J Biol Chem. 1999 Sep 3;274(36):25291-6 [10464253.001]
  • [Cites] Medicine (Baltimore). 1961 Feb;40:1-30 [13734791.001]
  • [Cites] Arthritis Rheum. 2004 Dec;50(12):3762-71 [15593206.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1479-86 [15851489.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1355-9 [15867089.001]
  • [Cites] Arthritis Rheum. 2005 Jun;52(6):1794-803 [15934079.001]
  • [Cites] Nucl Med Commun. 2006 Mar;27(3):205-11 [16479239.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):581-92 [16899778.001]
  • [Cites] Nat Clin Pract Rheumatol. 2006 Jan;2(1):28-34 [16932649.001]
  • [Cites] Ann Rheum Dis. 2006 Nov;65(11):1427-32 [16707534.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):4218-31 [17158877.001]
  • [Cites] Crit Care Med. 2007 May;35(5):1369-75 [17414728.001]
  • [Cites] Arthritis Rheum. 2007 Jun;56(6):1954-65 [17530721.001]
  • [Cites] Gut. 2007 Dec;56(12):1706-13 [17675327.001]
  • [Cites] Ann Rheum Dis. 2008 Mar;67(3):302-8 [17947302.001]
  • [Cites] Nat Clin Pract Rheumatol. 2007 Jul;3(7):382-90 [17599072.001]
  • [Cites] Ann Rheum Dis. 2007 Aug;66(8):1020-5 [17223658.001]
  • [Cites] J Leukoc Biol. 2001 Jun;69(6):986-94 [11404386.001]
  • (PMID = 19035478.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AR041138-05
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / S100 Proteins; 0 / S100A12 Protein; 0 / S100A12 protein, human
  • [Other-IDs] NLM/ NIHMS58669; NLM/ PMC2680303
  •  go-up   go-down


76. Zhang JY, Lü T, Yang JC, Pan L, Luo JM, Yang L, Yao L, Dong ZR, Xu SR: Comparative study of expressions of cytoplasmic CD79a and other B-lymphoid immunomarkers in acute leukemic cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec;13(6):954-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the expression of cytoplasmic CD79a (CyCD79a) and other commonly used B-lymphoid immunomarkers including cytoplasmic CD22 (CyCD22), CD19, CD20 and CD10 in various acute leukemia cells and to define the most sensitive and specific markers in the diagnosis of precursor B-cell acute lymphoblastic leukemia (pB-ALL), the immunophenotypic data from 221 de novo adult and pediatric acute leukemia patients as studied using multi-parameter flow cytometry in addition to routine morphologic and enzyme cytochemical assay, were retrospectively analyzed.
  • At the same time, none (0%) of all 147 cases of acute myeloid leukemia (AML) and 15 cases of precursor T-cell acute leukemia (pT-ALL) was positive for CyCD22.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403258.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD79; 0 / Biomarkers, Tumor; 0 / Sialic Acid Binding Ig-like Lectin 2
  •  go-up   go-down


77. Okada A, Hatori M, Hosaka M, Watanuki M, Itoi E: Secondary osteosarcoma arising after treatment for childhood hematologic malignancies. Ups J Med Sci; 2009;114(4):249-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secondary osteosarcoma arising after the treatment of hematologic malignancies other than Hodgkin's lymphoma is rare.
  • We report two cases of secondary osteosarcoma arising after treatment for childhood hematologic malignancies (non-Hodgkin's lymphoma and lymphoblastic leukemia).
  • A 10-year-old boy, at the age of 3, was diagnosed with non-Hodgkin's lymphoma.
  • A 26-year-old man, at the age of 6, was diagnosed as having acute lymphoblastic leukemia (ALL).
  • [MeSH-minor] Adult. Alkaline Phosphatase / blood. Biomarkers, Tumor / blood. Child. Humans. Lymphoma, T-Cell / therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1972 Oct;54(7):1479-89 [4510800.001]
  • [Cites] Eur J Surg Oncol. 2009 Oct;35(10):1030-6 [19232880.001]
  • [Cites] Skeletal Radiol. 1982;8(4):279-83 [6293097.001]
  • [Cites] J Clin Pathol. 1987 Apr;40(4):398-403 [3584482.001]
  • [Cites] N Engl J Med. 1987 Sep 3;317(10):588-93 [3475572.001]
  • [Cites] Tumori. 1987 Aug 31;73(4):331-6 [3477902.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):339-47 [2822073.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):193-201 [1985716.001]
  • [Cites] Oncology (Williston Park). 1991 May;5(5):135-41; discussion 142, 147-8 [1831995.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] Clin Orthop Relat Res. 1992 Jan;(274):275-81 [1729013.001]
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] Eur J Radiol. 2001 Jun;38(3):235-48 [11399379.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2074-9; discussion 2079-81 [11597387.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1959-66 [11745271.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Oct;24(7):572-4 [12368699.001]
  • [Cites] Int J Clin Oncol. 2002 Oct;7(5):318-21 [12402067.001]
  • [Cites] Bone Marrow Transplant. 2003 Mar;31(5):353-9 [12634726.001]
  • [Cites] Acta Paediatr Scand. 1991 Dec;80(12):1220-8 [1785295.001]
  • [Cites] Clin Chim Acta. 1991 Sep 14;201(1-2):27-33 [1790624.001]
  • [Cites] J Bone Joint Surg Am. 1992 Aug;74(7):1079-83 [1522094.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1224-30 [8435797.001]
  • [Cites] Ann Clin Biochem. 1993 Jul;30 ( Pt 4):355-72 [8379650.001]
  • [Cites] BMJ. 1993 Oct 23;307(6911):1030-6 [8251777.001]
  • [Cites] Oncology. 1996 Jul-Aug;53(4):275-80 [8692530.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Int J Cancer. 1998 Jul 29;77(3):370-7 [9663598.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1169-74 [16054775.001]
  • [Cites] Cancer. 1979 Jun;43(6):2178-81 [287547.001]
  • (PMID = 19961270.001).
  • [ISSN] 2000-1967
  • [Journal-full-title] Upsala journal of medical sciences
  • [ISO-abbreviation] Ups. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.1 / Alkaline Phosphatase
  • [Other-IDs] NLM/ PMC2852780
  •  go-up   go-down


78. Tageja N, Valent J, Bentley G, Zonder J: Precursor T cell acute lymphoblastic lymphoma presenting as bilateral facial nerve palsy. Chemotherapy; 2010;56(3):258-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor T cell acute lymphoblastic lymphoma presenting as bilateral facial nerve palsy.
  • [MeSH-major] Facial Nerve Diseases / diagnosis. Facial Paralysis / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Stem Cells / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551643.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


79. Brcić I, Labar B, Perić-Balja M, Basić-Kinda S, Nola M: Terminal deoxynucleotidyl transferase negative T-cell lymphoblastic lymphoma in aleukemic patient. Int J Hematol; 2008 Sep;88(2):189-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Terminal deoxynucleotidyl transferase negative T-cell lymphoblastic lymphoma in aleukemic patient.
  • Precursor lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) is a malignant neoplasm of precursor lymphocytes of T- or B-cell phenotype.
  • [MeSH-major] Biomarkers, Tumor / metabolism. DNA Nucleotidylexotransferase / metabolism. Lymph Nodes / pathology. Lymphatic Diseases / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Biopsy. Bone Marrow Cells / cytology. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4379-85 [12036865.001]
  • [Cites] Hum Pathol. 1997 Oct;28(10):1158-65 [9343323.001]
  • [Cites] Exp Mol Pathol. 2006 Oct;81(2):162-5 [16908018.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jan;124(1):92-7 [10629138.001]
  • [Cites] J Pathol. 1997 May;182(1):86-91 [9227346.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jan;127(1):42-8 [12521365.001]
  • (PMID = 18512118.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.31 / DNA Nucleotidylexotransferase
  •  go-up   go-down


80. Rajić V, Aplenc R, Debeljak M, Prestor VV, Karas-Kuzelicki N, Mlinaric-Rascan I, Jazbec J: Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma; 2009 Oct;50(10):1693-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hypothesis was tested in a cohort of 76 long-term survivals of acute lymphoblastic leukemia in childhood.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cardiomyopathies / genetics. Genetic Association Studies. Heart / drug effects. Myocardium / pathology. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Survivors
  • [MeSH-minor] Adolescent. Adult. Anthracyclines / administration & dosage. Anthracyclines / adverse effects. Catalase / genetics. Child. Child, Preschool. Cohort Studies. Female. Genotype. Glutathione Transferase / genetics. Humans. Infant. Male. Oxidative Stress. Reactive Oxygen Species / adverse effects. Superoxide Dismutase / genetics. Young Adult


81. Meijerink JP: Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol; 2010 Sep;23(3):307-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia.
  • Mutually exclusive oncogenic rearrangements may delineate specific T-cell acute lymphoblastic leukaemia (T-ALL) subgroups, and so far at least 4 molecular-cytogenetic subgroups have been identified, i.e. the TAL/LMO, the TLX1/HOX11, the TLX3/HOX11L2 and the HOXA subgroups.
  • A fifth group with an immature immunophenotype that can be predicted by an early T-cell precursor signature has also been identified, and has been associated with poor outcome.
  • These strong associations urge the need to extensively study oncogenic rearrangements and immunophenotypic markers in relation to outcome for future treatment protocols, both for paediatric as well as adult T-ALL patients.
  • [MeSH-major] Gene Rearrangement. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 21112032.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / NOTCH1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptor, Notch1; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


82. Meier M, den Boer ML, Hall AG, Irving JA, Passier M, Minto L, van Wering ER, Janka-Schaub GE, Pieters R: Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia. Leukemia; 2005 Nov;19(11):1887-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia.
  • The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype.
  • Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL) that are linked to drug resistance and clinical outcome.
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA-Binding Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / genetics. Polymorphism, Single Nucleotide. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antibiotics, Antineoplastic / pharmacology. Ataxia Telangiectasia Mutated Proteins. Case-Control Studies. Child. Child, Preschool. Daunorubicin / pharmacology. Disease-Free Survival. Drug Resistance, Neoplasm / genetics. Female. Gene Expression Profiling. Genetic Predisposition to Disease. Humans. Infant. Leukocyte Count. Male. Middle Aged. Phenotype. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors

  • Genetic Alliance. consumer health - Ataxia.
  • Genetic Alliance. consumer health - Ataxia Telangiectasia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2006 Mar;20(3):526-7; author reply 527 [16408093.001]
  • (PMID = 16167060.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


83. Advani AS, Jin T, Ramsingh G, Tiu R, Saber W, Theil K, Sobecks R, Sekeres M, Copelan E, Sungren S, Tripp B, Kalaycio M: Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia. Leuk Lymphoma; 2008 Aug;49(8):1560-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Cytogenetic Analysis. Humans. Middle Aged. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18766970.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


84. Keane C, Henden A, Mills T, Wood P: Myeloid and lymphoid neoplasm with FGFR1 abnormality. Br J Haematol; 2009 May;145(4):440
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Leukemia, Myeloid / genetics. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Fibroblast Growth Factor, Type 1 / genetics
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 13. Chromosomes, Human, Pair 8. Gene Rearrangement. Humans. Male. Syndrome. Translocation, Genetic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19076174.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1
  •  go-up   go-down


85. Ling JY, Sun XF, Yan SL, He LR, Zhen ZJ, Xia Y: [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. Ai Zheng; 2007 Apr;26(4):418-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Diagnosis of lymphocytic leukemia and non-Hodgkin's lymphoma (NHL) is based on bone marrow morphology.
  • RESULTS: In 45 cases of precursor B lymphoblastic leukemia/lymphoma (B-ALL/LBL), the antigens were mainly CD19, CD10, TdT, CD34, HLA-DR, and CD20.
  • In 32 cases of precursor T lymphoblastic leukemia/lymphoma (T-ALL/LBL), the antigens were mainly CD7, CD5, cytoplasmic (Cy)CD3, TdT, CD34, surface CD3 (sCD3), and HLA-DR.
  • Of the 77 cases of precursor ALL/LBL, 28(36.4%) expressed myeloid-associated antigens, such as CD13 and CD33; 9 (20.0%) cases of B-ALL/LBL coexpressed CD20 and CD34; 28(87.5%) cases of T-ALL/LBL coexpressed cyCD3 and TdT.
  • Among the 35 cases of mature B-cell malignancies, 17 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) mainly expressed CD19, CD20, CD5, HLA-DR, with coexpression of CD19 and CD5; 4 cases of diffuse large B-cell lymphoma (DLBCL) mainly expressed CD19, CD20, CD10, and HLA-DR; 3 cases of Burkitt's lymphoma (BL) mainly expressed CD19, CD10, CD20, and sIgM; 1 case of mantle cell lymphoma (MCL) expressed CD5, CD19, CD20, and HLA-DR.
  • Among the 10 mature T-cell malignancies, 5 cases of unspecialied peripheral T-cell lymphoma (PTCL) mainly expressed sCD3, CD5 and CD7, CD4 or CD8; 1 case of anaplastic large cell lymphoma (ALCL) expressed sCD3 and HLA-DR; 4 cases of NK/T-cell malignancies expressed CD56 and HLA-DR, CD4 or CD8 or CD7.
  • [MeSH-major] Antigens, CD / analysis. Bone Marrow / immunology. Immunophenotyping. Leukemia, Lymphoid / immunology. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Flow Cytometry. HLA-DR Antigens / analysis. Humans. Infant. Male. Middle Aged. Young Adult


86. Inamoto Y, Teramoto T, Shirai K, Tsukamoto H, Sanda T, Miyamura K, Yamamori I, Hirabayashi N, Kodera Y: Severe hypercholesterolemia associated with decreased hepatic triglyceride lipase activity and pseudohyponatremia in patients after allogeneic stem cell transplantation. Int J Hematol; 2005 Nov;82(4):362-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 55-year-old woman with Ph-negative acute lymphoblastic leukemia in primary induction failure received allogeneic peripheral blood stem cell transplantation from her HLA-compatible sister.
  • [MeSH-major] Hypercholesterolemia / etiology. Hyponatremia / etiology. Lipase / metabolism. Liver / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation / adverse effects
  • [MeSH-minor] ABO Blood-Group System. Adult. Blood Group Incompatibility. Female. Humans. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Hypercholesterolemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Clin Lab Sci. 1998 Dec;35(6):547-72 [9885775.001]
  • [Cites] Gastroenterology. 1985 Dec;89(6):1266-78 [4054519.001]
  • [Cites] Acta Med Scand. 1986;219(5):435-47 [3739751.001]
  • [Cites] Pathology. 1986 Jan;18(1):158-9 [3523399.001]
  • [Cites] Bone Marrow Transplant. 1996 Aug;18(2):457-9 [8864464.001]
  • [Cites] J Lipid Res. 2004 Nov;45(11):2116-22 [15314101.001]
  • [Cites] Bone Marrow Transplant. 2005 Jan;35(1):85-9 [15531904.001]
  • [Cites] Clin Liver Dis. 1999 Aug;3(3):651-68, x [11291243.001]
  • [Cites] Atherosclerosis. 1997 Jun;131(2):203-10 [9199273.001]
  • [Cites] Gastroenterology. 1990 May;98(5 Pt 1):1351-7 [2323525.001]
  • [Cites] N Engl J Med. 2003 Oct 9;349(15):1465-9 [14534340.001]
  • [Cites] Atherosclerosis. 2000 Apr;149(2):395-401 [10729390.001]
  • [Cites] Hepatology. 1985 Mar-Apr;5(2):286-92 [3920136.001]
  • [Cites] J Clin Invest. 1976 May;57(5):1248-60 [816809.001]
  • [Cites] Nutrition. 1997 May;13(5):417-21 [9225333.001]
  • [Cites] Metabolism. 1991 Oct;40(10):1052-6 [1943731.001]
  • [Cites] Can J Cardiol. 2000 Apr;16(4):505-11 [10787466.001]
  • [Cites] Acta Med Okayama. 1979 Aug;33(4):269-85 [227230.001]
  • [Cites] Atherosclerosis. 1982 Nov;45(2):161-79 [6961921.001]
  • [Cites] Baillieres Clin Endocrinol Metab. 1990 Dec;4(4):807-32 [2082907.001]
  • [Cites] Kidney Int Suppl. 1999 Jul;71:S22-4 [10412730.001]
  • [Cites] Transplantation. 1994 May 27;57(10):1479-83 [8197611.001]
  • [Cites] Metabolism. 1985 Sep;34(9):832-5 [4033424.001]
  • [Cites] Eur J Clin Invest. 1977 Dec;7(6):557-62 [415876.001]
  • [Cites] Clin Chim Acta. 1996 Jan 15;244(1):1-15 [8919198.001]
  • [Cites] J Immunol Methods. 2000 Feb 21;235(1-2):41-51 [10675756.001]
  • (PMID = 16298832.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / ABO Blood-Group System; EC 3.1.1.3 / Lipase
  •  go-up   go-down


87. Mancini M, Scappaticci D, Cimino G, Nanni M, Derme V, Elia L, Tafuri A, Vignetti M, Vitale A, Cuneo A, Castoldi G, Saglio G, Pane F, Mecucci C, Camera A, Specchia G, Tedeschi A, Di Raimondo F, Fioritoni G, Fabbiano F, Marmont F, Ferrara F, Cascavilla N, Todeschini G, Nobile F, Kropp MG, Leoni P, Tabilio A, Luppi M, Annino L, Mandelli F, Foà R: A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood; 2005 May 1;105(9):3434-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol.
  • The Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) 0496 protocol, through the central handling of bone marrow samples at presentation, allowed us to combine cytogenetic and molecular information on a large series of adults with acute lymphoblastic leukemia (ALL) treated homogeneously, enabling us to define as broadly as possible their genetic profile and to determine the impact on outcome of the cytogenetic-molecular signature.
  • This study highlights the importance of a combined cytogenetic-molecular profiling of adult ALL at presentation as a critical independent determinant of their outcome, providing further evidence of the necessity of a risk-adapted therapeutic algorithm for an optimal management of these patients.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Chromosome Aberrations. Classification. Cytogenetic Analysis. Female. Humans. Karyotyping. Male. Middle Aged. Oncogene Proteins, Fusion / analysis. Ploidies. Prognosis. Risk Factors. Survival Analysis. Treatment Outcome


88. Appel IM, den Boer ML, Meijerink JP, Veerman AJ, Reniers NC, Pieters R: Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood; 2006 Jun 1;107(11):4244-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia.
  • L-asparaginase (L-Asp) is an effective drug for treatment of children with acute lymphoblastic leukemia (ALL).
  • No significant difference of AS mRNA up-regulation was found between precursor B- and T-ALL or between hyperdiploids, TEL/AML1 rearranged ALL or absence of genetic abnormalities.
  • [MeSH-major] Asparaginase / pharmacology. Aspartate-Ammonia Ligase / genetics. Polyethylene Glycols / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Up-Regulation / drug effects
  • [MeSH-minor] Adolescent. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Female. Humans. Infant. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / pathology. Male. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Neoplasm / analysis. RNA, Neoplasm / drug effects. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497975.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Neoplasm; 0 / pegaspargase; 30IQX730WE / Polyethylene Glycols; EC 3.5.1.1 / Asparaginase; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


89. Mandac I, Kolonić SO, Vrhovac R, Lasan-Trcić R, Jakelić-Pitesa J, Kardum-Skelin I: T-lymphoblastic lymphoma with an unusual t(8;14)(q24;q11)--case report. Coll Antropol; 2010 Mar;34(1):265-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-lymphoblastic lymphoma with an unusual t(8;14)(q24;q11)--case report.
  • Cytogenetic abnormalities seen at presentation of acute lymphoblastic leukemia or lymphoblastic lymphoma (ALL/ LBL) are associated with distinct clinical and hematologic disease entities.
  • Based on these findings, diagnosis of T lymphoblastic non Hodgkin lymphoma was established.
  • [MeSH-major] Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosome Aberrations. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 8. Fatal Outcome. Humans. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Male. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432760.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


90. Imataki O, Koike A, Iwabu M, Shintani T, Waki F, Ohue Y, Ohnishi H, Ishida T: [Limited but potential efficacy by graft-versus-leukemia (GVL) for Pro T-ALL]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1911-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a 22-year-old male diagnosed with pro T-acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Graft vs Leukemia Effect / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Treatment Failure. Young Adult

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011341.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


91. Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll WL: A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia; 2009 Dec;23(12):2259-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This Phase I study of clofarabine with etoposide and cyclophosphamide for children with relapsed/refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) was conducted to determine the maximum tolerated dose (MTD), dose-limiting toxicities and the recommended phase 2 doses (RP2Ds).
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Child. Child, Preschool. Drug-Induced Liver Injury. Hematopoietic Stem Cell Transplantation. Humans. Infant. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / drug therapy. Maximum Tolerated Dose. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19741725.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 6PLQ3CP4P3 / Etoposide; 762RDY0Y2H / clofarabine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


92. Hagino T, Kaito K, Asai O, Dobashi N, Yano S, Takei Y, Sugiyama K, Saito T, Okawa Y, Aiba K, Usui N: [Pseudoleukocytosis and pseudothrombocytosis caused by fragmentation of leukemic cells in tumor lysis syndrome]. Rinsho Ketsueki; 2007 Dec;48(12):1559-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a 22-year-old woman with acute lymphoblastic leukemia (ALL) complicated with TLS, in whom elevation of leukocytes and platelet count was observed due to fragmented leukocytes.
  • [MeSH-minor] Adult. Female. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18203517.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


93. Tjønnfjord GE, Gedde-Dahl T 3rd, Heldal D, Brinch L: Treatment outcome in adults with acute lymphoblastic leukemia: 50% long-term disease-free survival. Leukemia; 2007 Oct;21(10):2203-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in adults with acute lymphoblastic leukemia: 50% long-term disease-free survival.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunophenotyping. Male. Middle Aged. Recurrence. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525727.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


94. Sandler ES, Homans A, Mandell L, Amylon M, Wall DA, Devidas M, Buchanan GR, Lipton JM, Billett AL: Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a pediatric oncology group pilot feasibility study. J Pediatr Hematol Oncol; 2006 Apr;28(4):210-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation after first marrow relapse of non-T, non-B acute lymphoblastic leukemia: a pediatric oncology group pilot feasibility study.
  • BACKGROUND: Relapsed acute lymphoblastic leukemia (ALL) in children is associated with a poor outcome, especially for those patients whose relapse occurs during the first 36 months after diagnosis.
  • [MeSH-major] Bone Marrow / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols. Child. Child, Preschool. Female. Humans. Male. Pilot Projects. Recurrence. Treatment Outcome


95. Bielen D, Mortelé K, Peters H, Lombard D, Ros R: Small bowel obstruction secondary to disseminated candidiasis in an immunocompromised patient: radiologic-pathologic correlation. JBR-BTR; 2005 Jan-Feb;88(1):20-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on a case of a 33-year-old immunocompromised woman with a history of recurrent T-cell lymphoblastic lymphoma, which presented with abdominal pain.
  • [MeSH-minor] Adult. Enteritis / microbiology. Fatal Outcome. Female. Humans. Lymphoma, T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792164.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


96. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL: Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol; 2008 Aug 20;26(24):3971-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
  • PURPOSE: Treatment of childhood relapsed acute lymphoblastic leukemia (ALL) remains a significant challenge.
  • CONCLUSION: The AALL01P2 regimen is a tolerable and active reinduction platform, suitable for testing in combination with novel agents in B-precursor ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Sep 1;96(5):1709-15 [10961868.001]
  • [Cites] Med Pediatr Oncol. 2000 May;34(5):313-8 [10797352.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Cancer. 1980 Jun 15;45(12):3090-4 [6930318.001]
  • [Cites] J Clin Oncol. 1985 Jul;3(7):998-1004 [3860629.001]
  • [Cites] Blood. 1988 Oct;72(4):1286-92 [3167209.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1166-72 [1878583.001]
  • [Cites] Blood. 1993 Feb 1;81(3):602-9 [8427957.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):470-6 [8341213.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]
  • [Cites] Med Pediatr Oncol. 1995 Nov;25(5):372-8 [7674994.001]
  • [Cites] Blood. 1996 Aug 1;88(3):831-7 [8704238.001]
  • [Cites] Med Pediatr Oncol. 1996 Dec;27(6):505-14 [8888809.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):671-7 [9401083.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):368-76 [15599932.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5750-62 [17179109.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]
  • [Cites] Pediatr Blood Cancer. 2004 Oct;43(5):571-9 [15382275.001]
  • [Cites] Haematologica. 2000 Nov;85(11 Suppl):47-53 [11268324.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [ErratumIn] J Clin Oncol. 2008 Oct 1;26(28): 4697.
  • (PMID = 18711187.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21CA110344; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC2654313
  •  go-up   go-down


97. Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood; 2005 Nov 15;106(10):3567-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features.
  • Most lymphoblastic lymphomas (LBLs) are regarded as neoplasms of immature T cells because they express cytoplasmic CD3 and frequently carry T-cell receptor (TCR) gene rearrangements.
  • Immature natural killer (NK) and T cells, however, have a common bipotent T/NK-cell precursor in the thymus, and NK cells also express cytoplasmic CD3.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Killer Cells, Natural / metabolism. Leukemia / metabolism. NK Cell Lectin-Like Receptor Subfamily D / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD3 / metabolism. Cell Differentiation. Child. Child, Preschool. Disease-Free Survival. Female. Gene Rearrangement, T-Lymphocyte. Humans. Infant. Infant, Newborn. Interleukin-15 / metabolism. Male. Microdissection / methods. Middle Aged. Receptors, Antigen, T-Cell / metabolism. Receptors, Interleukin-15. Receptors, Interleukin-2 / metabolism. T-Lymphocytes / metabolism. T-Lymphocytes / pathology. Thymus Gland / metabolism. Thymus Gland / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046525.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / IL15RA protein, human; 0 / Interleukin-15; 0 / KLRD1 protein, human; 0 / NK Cell Lectin-Like Receptor Subfamily D; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, Interleukin-15; 0 / Receptors, Interleukin-2
  •  go-up   go-down


98. Okada K, Nakae N, Kuramochi K, Yin SA, Ikeda M, Takami S, Hirata T, Goryo M, Numakunai S, Takeshima SN, Takahashi M, Tajima S, Konnai S, Onuma M, Aida Y: Bovine leukemia virus high tax molecular clone experimentally induces leukemia/lymphoma in sheep. J Vet Med Sci; 2005 Dec;67(12):1231-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bovine leukemia virus high tax molecular clone experimentally induces leukemia/lymphoma in sheep.
  • Only 1 case in H group became leukemic, and one case each of H and W groups developed lymphoma.
  • In No. 6, lesions of lymphoma were found only in the jejunum and heart.
  • Morphologically, small to middle-sized lymphocytic neoplastic (NP) cells were found in both cases, but lymphoblastic NP cells were found only in No. 3.
  • The results of this study indicate that inoculation of pBLV-IF can induce lymphocytic and lymphoblastic leukemia/lymphoma in sheep.
  • Additionally, it is suggested that the expression rate of tax gene is not associated with the development of leukemia/lymphoma in sheep experimentally inoculated with pBLV-IF.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16397381.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Glycoproteins; 0 / glycoprotein GP51
  •  go-up   go-down


99. He GS, Zhang XH, Yao L, Zhang R, Chen ZX, Wu DP, Sun AN, Jin ZM, Qiu HY, Hu XH: [Acute T cells lymphoblastic leukemia with a t(1;19)(q23;p13) and E2A-PBX1 in an adult: one case report and literature review]. Zhonghua Xue Ye Xue Za Zhi; 2009 Oct;30(10):675-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute T cells lymphoblastic leukemia with a t(1;19)(q23;p13) and E2A-PBX1 in an adult: one case report and literature review].
  • OBJECTIVE: To report a case of T cell acute lymphoblastic leukemia (ALL) with t(1;19)(q23;pl3) and E2A-PBX1 fusion gene, which is a characteristic translocation of childhood B cell ALL (B-ALL).
  • CONCLUSION: t(1;19)E2A-PBX1(+) can be implicated in adult T-ALL, besides childhood B-ALL.
  • [MeSH-major] Homeodomain Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Humans. Karyotyping. Male

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954663.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 146150-85-8 / E2A-Pbx1 fusion protein
  •  go-up   go-down


100. Beesley AH, Cummings AJ, Freitas JR, Hoffmann K, Firth MJ, Ford J, de Klerk NH, Kees UR: The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure. Br J Haematol; 2005 Nov;131(4):447-56